var title_f12_24_12672="Pressures mitral stenosis II";
var content_f12_24_12672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pressure tracings in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intracardiac pressures, measured simultaneosuly from the left atrium (LA) via a transeptal catheter and left ventricle (LV) in a patient with mitral stenosis, demonstrate a persistent diastolic pressure gradient (shaded area) between the LA and LV. The time for diastole (sec per beat), known as the diastolic filling period (DFP), and the mean gradient are used to compute the valve area from the Gorlin formula (mitral valve area = cardiac output &divide; [37.7 x DFP x heart rate x sq rt mean gradient]).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd ed. Mosby-Year Book, St. Louis, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12672=[""].join("\n");
var outline_f12_24_12672=null;
var title_f12_24_12673="Gastric prolapse";
var content_f12_24_12673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric prolapse due to slippage of gastric band",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Band slippage can result in prolapse of part of the stomach through the band, with varying degrees of gastric obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12673=[""].join("\n");
var outline_f12_24_12673=null;
var title_f12_24_12674="Nabothian cyst";
var content_f12_24_12674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colposcopic view of a Nabothian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cyst (the raised area between lines A+B) has a yellow hue and is covered by enlarged capillaries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kathryn F McGonigle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12674=[""].join("\n");
var outline_f12_24_12674=null;
var title_f12_24_12675="Neonatal testicular torsion";
var content_f12_24_12675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Intravaginal and extravaginal testicular torsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Neonatal testicular torsion is generally due to extravaginal torsion and testicular torsion in older children and adolsecents is due to intravaginal torsion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12675=[""].join("\n");
var outline_f12_24_12675=null;
var title_f12_24_12676="Flurandrenolide: Patient drug information";
var content_f12_24_12676=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flurandrenolide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/55/20340?source=see_link\">",
"     see \"Flurandrenolide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cordran&reg;;",
"     </li>",
"     <li>",
"      Cordran&reg; SP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cordran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702147",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flurandrenolide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3509602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on your face, underarms, or the groin area unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4042349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cream, lotion:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4042348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tape:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shave any hair in the area you will be putting the tape so that the tape sticks better and comes off easier.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not tear the tape. Always cut the tape.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042352",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a piece of tape that is a little bigger than the area to be covered.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042353",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the ends of the tape loosen, cut them off and replace with new tape.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shower or bathe before putting on new tape.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12488 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12676=[""].join("\n");
var outline_f12_24_12676=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173009\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173010\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016373\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016372\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016377\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016378\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016380\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016375\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016376\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016381\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016382\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/55/20340?source=related_link\">",
"      Flurandrenolide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_24_12677="Sulfasalazine: Patient drug information";
var content_f12_24_12677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulfasalazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     see \"Sulfasalazine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=see_link\">",
"     see \"Sulfasalazine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azulfidine EN-tabs&reg;;",
"     </li>",
"     <li>",
"      Azulfidine&reg;;",
"     </li>",
"     <li>",
"      Sulfazine;",
"     </li>",
"     <li>",
"      Sulfazine EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sulfasalazine&reg;;",
"     </li>",
"     <li>",
"      PMS-Sulfasalazine;",
"     </li>",
"     <li>",
"      Salazopyrin En-Tabs&reg;;",
"     </li>",
"     <li>",
"      Salazopyrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat rheumatoid arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Crohn's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702971",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sulfasalazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, porphyria, or trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may change the color of urine, sweat, and tears to yellow or orange color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain contact lenses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sperm counts and motility may be lowered. These go back to normal within 2 months after the drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you see tablet bits in the stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow enteric-coated tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11062 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12677=[""].join("\n");
var outline_f12_24_12677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223904\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028279\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028278\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028283\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028284\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028286\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028281\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028282\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028287\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028288\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=related_link\">",
"      Sulfasalazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=related_link\">",
"      Sulfasalazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_24_12678="Flurazepam: Pediatric drug information";
var content_f12_24_12678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurazepam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/3/27703?source=see_link\">",
"    see \"Flurazepam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/47/33524?source=see_link\">",
"    see \"Flurazepam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flurazepam&reg;;",
"     </li>",
"     <li>",
"      Dalmane&reg;;",
"     </li>",
"     <li>",
"      Som Pam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/3/27703?source=see_link\">",
"      see \"Flurazepam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;15 years: Dose not established; use not recommended by manufacturer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;15 years: 15 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 15-30 mg at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 15 mg, 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F173101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016721s077lbl.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016721s077lbl.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; administer dose at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F7813923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dalmane&reg;: Store at controlled room temperature at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Generic: Store at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light and moisture; dispense in tightly closed, light-resistant container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of insomnia (FDA approved in ages &ge;15 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flurazepam may be confused with temazepam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dalmane&reg; may be confused with Demulen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F173106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, flushing, hypotension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apprehension, ataxia, confusion, depression, dizziness, drowsiness, euphoria, faintness, falling, hallucinations, hangover effect, headache, irritability, lightheadedness, memory impairment, nervousness, paradoxical reactions, restlessness, slurred speech, staggering, talkativeness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased/decreased, bitter taste, constipation, diarrhea, GI pain, heartburn, nausea, salivation increased/excessive, upset stomach, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, cholestatic jaundice, total bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Body/joint pain, dysarthria, reflex slowing, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, burning eyes, difficulty focusing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, drug dependence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis, angioedema, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flurazepam or any component (there may be cross-sensitivity with other benzodiazepines), pregnancy, pre-existing CNS depression, respiratory depression, narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with depression, chronic pulmonary insufficiency, impaired renal or hepatic function, or low albumin. May cause CNS depression impairing physical and mental capabilities; patients should be cautioned about performing tasks which require mental alertness (operating machinery or driving). Use with caution in patients receiving other CNS depressants or in patients with a history of drug dependence.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4805285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patient carefully for medical or psychiatric causes of insomnia prior to initiation of drug treatment; failure of flurazepam to treat insomnia (after 7-10 days of therapy), a worsening of insomnia, the emergence of behavioral changes, or thinking abnormalities may indicate a medical or psychiatric illness requiring evaluation; these effects also have been reported with flurazepam use. Due to possible adverse effects, use lowest effective dose. Abrupt discontinuation after prolonged use may result in withdrawal symptoms or rebound insomnia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity reactions including anaphylaxis and angioedema may occur. Hazardous sleep-related activities, such as sleep-driving (driving while not fully awake without any recollection of driving), preparing and eating food, and making phone calls while asleep have also been reported. Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3921683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although information specific to flurazepam has not been located, all benzodiazepines are assumed to cross the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines. Neonatal depression has been observed, specifically following exposure to flurazepam when used maternally for 10 consecutive days prior to delivery. Serum levels of N-desalkylflurazepam were measurable in the infant during the first 4 days of life. Use of flurazepam during pregnancy is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA, which is a major inhibitory neurotransmitter in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypnotic effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 15-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 7-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 3.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to N-desalkylflurazepam (active) and N-hydroxyethylflurazepam",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flurazepam: Mean: 2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desalkylflurazepam: Single dose: 74-90 hours; multiple doses: 111-113 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     Flurazepam: 30&ndash;60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desalkylflurazepam: 10.6 hours (range: 7.6-13.6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-hydroxyethylflurazepam: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine: N-hydroxyethylflurazepam (22% to 55%); N-desalkylflurazepam (&lt;1%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/47/33524?source=see_link\">",
"      see \"Flurazepam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of flurazepam. Avoid alcohol and other CNS depressants. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Take dose immediately before bedtime (not sooner). May also cause daytime drowsiness. May cause dry mouth. May cause hypersensitivity reactions. May cause hazardous sleep-related activities (ie, driving, preparing and eating foods, and making phone calls while not fully awake).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cooper SF and Drolet D, \"Protein Binding of Flurazepam and Its Major Metabolites in Plasma,&rdquo;",
"      <i>",
"       Curr Ther Res",
"      </i>",
"      , 1982, 32(5):757-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenblatt DJ, Harmatz JS, Engelhardt N, et al, \"Pharmacokinetic Determinants of Dynamic Differences Among Three Benzodiazepine Hypnotics. Flurazepam, Temazepam, and Triazolam,\"",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 1989, 46(4):326-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/24/12678/abstract-text/2564763/pubmed\" id=\"2564763\" target=\"_blank\">",
"        2564763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, \"Pharmacokinetic Drug Data,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/24/12678/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13317 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12678=[""].join("\n");
var outline_f12_24_12678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052956\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052951\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173044\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173028\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173101\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874503\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052961\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7813923\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052960\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173108\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173106\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052965\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052950\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4805285\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173095\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173037\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3921683\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052949\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052963\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052964\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052955\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13317|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/3/27703?source=related_link\">",
"      Flurazepam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/47/33524?source=related_link\">",
"      Flurazepam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_24_12679="CMV pneumonia";
var content_f12_24_12679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CMV pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph showing multifocal patchy pneumonia due to cytomegalovirus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12679=[""].join("\n");
var outline_f12_24_12679=null;
var title_f12_24_12680="Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes";
var content_f12_24_12680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12680/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12680/contributors\">",
"     Colin A Sieff, MB, BCh, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12680/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12680/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/24/12680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The family of glycoproteins known as the hematopoietic growth factors (HGFs) plays a major role in the proliferation, differentiation, and survival of primitive hematopoietic stem and progenitor cells, as well as in functional activation of some mature cells. These effects are mediated by high affinity binding of the HGFs to specific receptors expressed on the surface of the target cells.",
"   </p>",
"   <p>",
"    Among the recombinant human (rh) growth factors that are available, interleukin (IL)-3 and granulocyte-macrophage colony-stimulating factor (rhGM-CSF) broadly stimulate hematopoiesis, while erythropoietin (EPO),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (rhG-CSF), and thrombopoietin (TPO) are more lineage-specific, stimulating the production of red blood cells, polymorphonuclear leukocytes, and platelets, respectively (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INHERITED BONE MARROW FAILURE SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of HGFs in the treatment of inherited bone marrow failure syndromes will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/1\">",
"     1",
"    </a>",
"    ]. An overview of the actions and potential toxicity of the HGFs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fanconi anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fanconi anemia is the most common type of congenital aplastic anemia. It is a familial condition characterized by pancytopenia, macrocytic anemia, and physical abnormalities. Multiple genes appear to be responsible for this illness since at least 11 complementation groups (FA-A to FA-L) have been described. There is evidence that FANC-A, -C, -E, -F, and -G form a complex that monoubiquinates FANC-D2 and leads to its co-localization with BRCA1 and BRCA2 (FANC-D1) in nuclear foci following genotoxic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recombinant hIL-3, rhGM-CSF, and rhG-CSF have been evaluated in the treatment of Fanconi anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. All three HGFs raise the neutrophil count in most pancytopenic patients, but the platelet count and hemoglobin concentration are generally unaffected. In one study, for example, 12 neutropenic patients with Fanconi were treated with rhG-CSF (5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day initially and then every other day) for 40 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/5\">",
"     5",
"    </a>",
"    ]. All had an increase in absolute neutrophil count (ANC), and eight maintained an ANC above",
"    <span class=\"nowrap\">",
"     1500/microL.",
"    </span>",
"    Four untransfused patients had an increase in hemoglobin concentration of at least 2.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and four had an increase in platelet count that was not maintained when the rhG-CSF dose was reduced. There was also an increase in CD34+ cells in the bone marrow, indicating stimulation of the early stages of hematopoiesis. Androgens are also used to stimulate hematopoiesis in FA, with responses in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H868984\">",
"    <span class=\"h2\">",
"     Dyskeratosis congenita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyskeratosis congenita (DC) is an inherited bone marrow failure disorder characterized by the triad of abnormal skin pigmentation, nail dystrophy, and leukoplakia, with a high rate of aplastic anemia, which is the major cause of mortality and usually appears in the first two decades. Responses to G-CSF and to androgens are similar to those observed in FA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H13#H13\">",
"     \"Inherited aplastic anemia in children\", section on 'Dyskeratosis congenita'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diamond-Blackfan anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diamond-Blackfan anemia (DBA) is a congenital form of pure red cell aplasia in which the erythroid precursors are reduced or absent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/8\">",
"     8",
"    </a>",
"    ]. The pathogenesis of this disorder is uncertain. In vitro studies show that hematopoietic stem cells from patients with DBA can be induced to differentiate into the granulocyte and megakaryocyte, but not the erythroid lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/9\">",
"     9",
"    </a>",
"    ]. This finding is not consistent, however, and many patients have detectable erythroid progenitors, particularly if stem cell factor (SCF) and IL-3 are included in the cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Approximately 25 percent of patients have a mutation on chromosome 19 that involves the gene encoding the ribosomal protein S19 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H3#H3\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Diamond-Blackfan anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that DBA is associated with a deficiency of EPO, IL-3, or GM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/9,13\">",
"     9,13",
"    </a>",
"    ] or an abnormality of c-kit or its ligand SCF (also called Kit ligand or Steel factor) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .) Despite these observations, it remains possible that pharmacologic doses of these factors might stimulate erythropoiesis. Recombinant human EPO does not appear to be beneficial; in one series, for example, no reticulocyte or hemoglobin responses were observed in nine patients treated with doses as high as 2000",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, some patients appear to respond to rhIL-3. Summarizing the results of four studies, significant erythroid responses were seen in 10 of 96 patients (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. In one of these reports, four responses were seen in 18 patients treated with rhIL-3 (0.5 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    SQ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/17\">",
"     17",
"    </a>",
"    ]. Two responders developed deep vein thromboses necessitating discontinuation of treatment, while the other two patients maintained their responses, one on maintenance rhIL-3 for 31 months and one off treatment for 12 months after 30 months of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Amegakaryocytic thrombocytopenia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;The congenital form of amegakaryocytic thrombocytopenia (AMT) is a rare disease that presents in infancy or early childhood with thrombocytopenia, anemia, and progression to pancytopenia. Bone marrow megakaryocytes are absent or extremely scarce; in at least some patients with the congenital form this is due to mutations in the gene for the thrombopoietin receptor (c-mpl) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum levels of thrombopoietin (TPO) are elevated in AMT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/21\">",
"     21",
"    </a>",
"    ]; children with congenital AMT do not respond to TPO but may respond to rhIL-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. As an example, a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    rhIL-3 dose escalation study was performed in five children with AMT, with or without sequential rhGM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/23\">",
"     23",
"    </a>",
"    ]. rhIL-3, but not the combination of rhIL-3 and rhGM-CSF, induced platelet responses in two patients, and improved bruising, bleeding, and transfusion requirements in the other three. The two platelet responders became unresponsive after several months of rhIL-3 maintenance (125 to 250",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day), while one patient became platelet transfusion independent after four months of therapy and had a sustained trilineage response for almost two years. Successful responses have also been described with PIXY321, an",
"    <span class=\"nowrap\">",
"     IL-3/GM-CSF",
"    </span>",
"    fusion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. In one report, trilineage responses were seen in 3 of 14 patients with AMT and other bone marrow failure syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/24\">",
"     24",
"    </a>",
"    ]. PIXY321 trials were discontinued because of lack of superiority to GM-CSF in a phase III study of chemotherapy in patients with advanced breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In practice, cytokines are rarely used in congenital AMT, and the treatment of choice is hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acquired",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an acquired, often cyclic form of AMT in adults (ie, acquired pure megakaryocytic aplasia) also associated with an isolated severe reduction or absence of megakaryocytes on bone marrow examination. This condition has been seen in patients with systemic lupus erythematosus, T-cell LGL leukemia, and eosinophilic fasciitis, and is associated with autoantibodies to the thrombopoietin receptor (c-Mpl) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. This condition may respond to treatment with immunosuppressive agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , antithymocyte globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. One patient failing treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and cyclosporine responded to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    , a nonpeptide thrombopoietin (TPO) mimetic that binds to and activates the TPO receptor at a different site from endogenous TPO [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical applications of thrombopoietic growth factors\", section on 'Eltrombopag (SB497115, Promacta/Revolade)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there is extensive experience with hematopoietic cell transplantation (HCT) in the congenital form of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], experience with HCT in the acquired form is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Severe congenital neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe congenital neutropenia (SCN), which occurs in dominant and recessive forms, is a disorder of myelopoiesis characterized by impaired neutrophil differentiation and absolute neutrophil counts below",
"    <span class=\"nowrap\">",
"     200/microL.",
"    </span>",
"    In contrast, monocytes and eosinophils are normal or increased. The bone marrow shows maturation arrest at the promyelocyte stage, and these cells are often atypical, with abnormal nuclei and vacuolated cytoplasm.",
"   </p>",
"   <p>",
"    The pathophysiology of neutropenia in SCN is uncertain, but 35 to 84 percent of patients have dominant or sporadic mutations in the neutrophil elastase gene (formerly called ELA2 but now known as ELANE) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/39\">",
"     39",
"    </a>",
"    ]. ELANE mutations appear to account for many cases of dominant SCN and all cases of cyclic neutropenia (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Cyclic neutropenia'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. SCN was first described as an autosomal recessive &ldquo;infantile genetic agranulocytosis&rdquo; by Rolf Kostmann [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/42\">",
"     42",
"    </a>",
"    ]. In 2007, more than 50 years later, this form of SCN, for which the name Kostmann disease should be reserved, was shown to be due to mutations in HAX1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with SCN develop mutations in the gene for the G-CSF receptor. However, these mutations, which lead to deletion of the cytoplasmic tail of the receptor, are acquired and may bear on the development of leukemia in these patients. The mutations are infrequent (15 to 20 percent of patients studied) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/44\">",
"     44",
"    </a>",
"    ] and induce an SCN phenotype in mice carrying a targeted mutation that reproduces that found in patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    G-CSF produces a remarkable increase in the neutrophil count in all patients and virtually abolishes episodes of serious bacterial and fungal infection that are common before treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. As an example, a multicenter phase III trial of rhG-CSF in 120 patients with severe chronic neutropenic disorders (including Kostmann disease, Shwachman-Diamond syndrome, and myelokathexis) showed complete responses (ANC",
"    <span class=\"nowrap\">",
"     &gt;1500/microL)",
"    </span>",
"    in 108 patients, partial responses in four, and failure to respond in eight [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/50\">",
"     50",
"    </a>",
"    ]. The dose necessary to maintain an ANC above",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    ranges from 3 to 15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day (median 5.6",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/51\">",
"     51",
"    </a>",
"    ]. The majority of patients respond to a G-CSF dose of 3 to 20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day, but about 25 percent of patients require higher doses (20 to 100",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) to achieve an ANC of",
"    <span class=\"nowrap\">",
"     &gt;1000/microL.",
"    </span>",
"    In comparison, rhGM-CSF is much less likely to raise the ANC, although it may increase the eosinophil and monocyte counts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two complications of SCN are the development of myelodysplastic syndrome or acute myeloid leukemia, and osteoporosis. Both appear to be complications of the underlying disease, unmasked by the increased duration of life with treatment. The risk of",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    increases over time (2.9 percent after six years, 8 percent after 12 years); after 10 years the cumulative incidence is 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/52\">",
"     52",
"    </a>",
"    ]. In this study, 29 percent of patients were classified as less-responsive; they required &gt;8",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day (the median dose) but did not achieve the median ANC of",
"    <span class=\"nowrap\">",
"     2188/microL",
"    </span>",
"    at 6 to 18 months, and were much more likely to develop",
"    <span class=\"nowrap\">",
"     MDS/AML:",
"    </span>",
"    40 percent at 10 years, compared with 11 percent of the more responsive patients whose ANC was above the median at less than the median dose. Thus, patients on long-term therapy with rhG-CSF should have yearly bone marrow and cytogenetic studies and measurement of bone density. The concern that rhG-CSF therapy might promote leukemogenesis has yet to be confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital neutropenia\", section on 'Severe congenital neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the approximately 10 percent of patients with SCN who are refractory to treatment with rhG-CSF and continue to have severe and often life-threatening bacterial infections, hematopoietic stem cell transplantation is the only currently available treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cyclic neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic neutropenia (CN) is a rare hematopoietic stem cell disease characterized by regular 21-day cyclic fluctuations in numbers of neutrophils, monocytes, eosinophils, lymphocytes, platelets, and reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients typically have recurrent episodes of fever, malaise, mucosal ulceration, and occasionally, life-threatening infections during periods of neutropenia. This disorder is thought to represent a stem cell regulatory defect since multiple cell lines are involved and the disease can be transferred from an affected human donor to a recipient during bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/54\">",
"     54",
"    </a>",
"    ]. Linkage analysis in familial CN mapped the locus to chromosome 19q13.3, a region that contains the neutrophil elastase gene ELANE, a chymotryptic serine protease of neutrophil and monocyte granules [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients with cyclic neutropenia have mutations of neutrophil elastase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]; mutations of this enzyme presumably lead to accelerated apoptosis of precursors and the cycling of neutrophil counts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      rhG-CSF has been used successfully in patients with cyclic neutropenia with a 10- to more than 20-fold increase in ANC and prevention of infection",
"     </li>",
"     <li>",
"      rhGM-CSF has not been as effective as rhG-CSF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1013919\">",
"    <span class=\"h2\">",
"     Shwachman-Diamond syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of rhG-CSF in this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link&amp;anchor=H25#H25\">",
"     \"Shwachman-Diamond syndrome\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic benign neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic benign neutropenia, also called chronic idiopathic neutropenia, is a disorder of myelopoiesis characterized by maturation arrest of neutrophil precursors in the bone marrow and ANCs that are usually between 200 and",
"    <span class=\"nowrap\">",
"     1000/microL;",
"    </span>",
"    other cell lineages are normal. The pathophysiology of this disorder is uncertain; a minority of patients have antineutrophil antibodies of undetermined pathogenetic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H9#H9\">",
"     \"Immune neutropenia\", section on 'Chronic idiopathic neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with chronic idiopathic neutropenia are asymptomatic, most likely a reflection of the considerable bone marrow reserve; neutrophils will frequently increase during infections. Therapy is restricted to patients with recurrent infections. rhG-CSF has been used successfully to treat small numbers of adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/44,59\">",
"     44,59",
"    </a>",
"    ]. In one study, for example, seven adults received a starting rhG-CSF dose of 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day and a maintenance dose that ranged from 0.1 to 8",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/60\">",
"     60",
"    </a>",
"    ]. All had a rapid increase in the ANC and maintenance therapy was associated with absence of severe infections at follow-up of up to 4.5 years. Similar results were obtained in six symptomatic children, all of whom were able to maintain a mean ANC above",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    and eliminate prophylactic antibiotics without serious infection at rhG-CSF doses ranging from 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    once weekly to 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12680/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6190803\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the recombinant human (rh) growth factors, interleukin (IL)-3 and granulocyte-macrophage colony-stimulating factor (rhGM-CSF) broadly stimulate hematopoiesis, while erythropoietin (EPO),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (rhG-CSF), and thrombopoietin (TPO) are more lineage-specific, stimulating the production of red blood cells, polymorphonuclear leukocytes, and platelets, respectively (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). Because of toxicity and inflammatory side effects, IL-3 is no longer in clinical use; similarly, TPO has been withdrawn from further clinical use because of the development of antibodies that caused thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fanconi anemia and dyskeratosis congenita",
"      </strong>",
"      ��� Recombinant G-CSF raises the neutrophil count in most patients who have residual hematopoiesis, but the platelet count and hemoglobin concentration are generally unaffected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fanconi anemia'",
"      </a>",
"      above.) Androgens such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10868?source=see_link\">",
"       oxymetholone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      can increase hemoglobin levels and platelet counts, but carry risks of masculinization and hepatic tumors.",
"     </li>",
"     <li>",
"      <strong>",
"       Diamond-Blackfan anemia",
"      </strong>",
"      ��� Some patients appear to respond to IL-3, although it is no longer available. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diamond-Blackfan anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Amegakaryocytic thrombocytopenia",
"      </strong>",
"      ��� Children with congenital amegakaryocytic thrombocytopenia do not respond to TPO but may respond to IL-3. Some subjects with the acquired disorder have responded to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      , a nonpeptide thrombopoietin (TPO) mimetic. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Amegakaryocytic thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Severe congenital neutropenia, cyclic neutropenia, and chronic benign neutropenia",
"      </strong>",
"      ��� These conditions have all responded to treatment with G-CSF to variable degrees (see above sections).",
"     </li>",
"     <li>",
"      <strong>",
"       Shwachman-Diamond syndrome",
"      </strong>",
"      ��� G-CSF has been successfully used in patients with Shwachman-Diamond syndrome and recurrent or life-threatening infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link&amp;anchor=H25#H25\">",
"       \"Shwachman-Diamond syndrome\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/1\">",
"      Gillio AP, Gabrilove JL. Cytokine treatment of inherited bone marrow failure syndromes. Blood 1993; 81:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/2\">",
"      D'Andrea AD. The Fanconi road to cancer. Genes Dev 2003; 17:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/3\">",
"      D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/4\">",
"      Guinan EC, Lopez KD, Huhn RD, et al. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr 1994; 124:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/5\">",
"      Rackoff WR, Orazi A, Robinson CA, et al. Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Blood 1996; 88:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/6\">",
"      Dufour C, Svahn J. Fanconi anaemia: new strategies. Bone Marrow Transplant 2008; 41 Suppl 2:S90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/7\">",
"      Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev 2008; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/8\">",
"      Willig TN, Gazda H, Sieff CA. Diamond-Blackfan anemia. Curr Opin Hematol 2000; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/9\">",
"      Bagnara GP, Zauli G, Vitale L, et al. In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia. Blood 1991; 78:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/10\">",
"      Abkowitz JL, Sabo KM, Nakamoto B, et al. Diamond-blackfan anemia: in vitro response of erythroid progenitors to the ligand for c-kit. Blood 1991; 78:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/11\">",
"      Sieff CA, Yokoyama CT, Zsebo KM, et al. The production of steel factor mRNA in Diamond-Blackfan anaemia long-term cultures and interactions of steel factor with erythropoietin and interleukin-3. Br J Haematol 1992; 82:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/12\">",
"      Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 1999; 21:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/13\">",
"      Hammond D, Keighley G. The erythrocyte-stimulating factor in serum and urine in congenital hypoplastic anemia. Am J Dis Child 1960; 100:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/14\">",
"      Abkowitz JL, Broudy VC, Bennett LG, et al. Absence of abnormalities of c-kit or its ligand in two patients with Diamond-Blackfan anemia. Blood 1992; 79:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/15\">",
"      Niemeyer CM, Baumgarten E, Holldack J, et al. Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia. Contrib Nephrol 1991; 88:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/16\">",
"      Ball SE, Tchernia G, Wranne L, et al. Is there a role for interleukin-3 in Diamond-Blackfan anaemia? Results of a European multicentre study. Br J Haematol 1995; 91:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/17\">",
"      Gillio AP, Faulkner LB, Alter BP, et al. Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood 1993; 82:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/18\">",
"      Olivieri NF, Feig SA, Valentino L, et al. Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. Blood 1994; 83:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/19\">",
"      Bastion Y, Bordigoni P, Debr&eacute; M, et al. Sustained response after recombinant interleukin-3 in diamond blackfan anemia. Blood 1994; 83:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/20\">",
"      Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999; 96:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/21\">",
"      Cremer M, Schulze H, Linthorst G, et al. Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. Ann Hematol 1999; 78:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/22\">",
"      Muraoka K, Ishii E, Tsuji K, et al. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol 1997; 96:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/23\">",
"      Guinan EC, Lee YS, Lopez KD, et al. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993; 81:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/24\">",
"      Taylor DS, Lee Y, Sieff CA, et al. Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. Br J Haematol 1998; 103:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/25\">",
"      O'Shaughnessy JA, Tolcher A, Riseberg D, et al. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood 1996; 87:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/26\">",
"      Lackner A, Basu O, Bierings M, et al. Haematopoietic stem cell transplantation for amegakaryocytic thrombocytopenia. Br J Haematol 2000; 109:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/27\">",
"      Al-Ahmari A, Ayas M, Al-Jefri A, et al. Allogeneic stem cell transplantation for patients with congenital amegakaryocytic thrombocytopenia (CAT). Bone Marrow Transplant 2004; 33:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/28\">",
"      King S, Germeshausen M, Strauss G, et al. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005; 131:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/29\">",
"      Kuwana M, Okazaki Y, Kajihara M, et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 2002; 46:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/30\">",
"      Katsumata Y, Suzuki T, Kuwana M, et al. Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis. Arthritis Rheum 2003; 48:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/31\">",
"      Kuwana M, Kaburaki J, Okazaki Y, et al. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/32\">",
"      Manoharan A, Williams NT, Sparrow R. Acquired amegakaryocytic thrombocytopenia: report of a case and review of literature. Q J Med 1989; 70:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/33\">",
"      Zent CS, Ratajczak J, Ratajczak MZ, et al. Relationship between megakaryocyte mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura. Br J Haematol 1999; 105:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/34\">",
"      el Saghir NS, Geltman RL. Treatment of acquired amegakaryocytic thrombocytopenic purpura with cyclophosphamide. Am J Med 1986; 81:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/35\">",
"      Lonial S, Bilodeau PA, Langston AA, et al. Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature. Bone Marrow Transplant 1999; 24:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/36\">",
"      Leach JW, Hussein KK, George JN. Acquired pure megakaryocytic aplasia report of two cases with long-term responses to antithymocyte globulin and cyclosporine. Am J Hematol 1999; 62:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/37\">",
"      Bulchandani D, Nachnani J, Belt R, Hinton S. Acquired pure megakaryocytic aplasia: report of a single case treated with mycophenolate mofetil. Am J Hematol 2007; 82:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/38\">",
"      Cela I, Miller IJ, Katz RS, et al. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE). Clin Adv Hematol Oncol 2010; 8:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/39\">",
"      Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000; 96:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/40\">",
"      Ancliff PJ, Gale RE, Watts MJ, et al. Paternal mosaicism proves the pathogenic nature of mutations in neutrophil elastase in severe congenital neutropenia. Blood 2002; 100:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/41\">",
"      Horwitz M, Benson KF, Duan Z, et al. Hereditary neutropenia: dogs explain human neutrophil elastase mutations. Trends Mol Med 2004; 10:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/42\">",
"      KOSTMANN R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl 1956; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/43\">",
"      Klein C, Grudzien M, Appaswamy G, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007; 39:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/44\">",
"      Tidow N, Pilz C, Teichmann B, et al. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Blood 1997; 89:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/45\">",
"      McLemore ML, Poursine-Laurent J, Link DC. Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia. J Clin Invest 1998; 102:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/46\">",
"      Hermans MH, Ward AC, Antonissen C, et al. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 1998; 92:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/47\">",
"      Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989; 320:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/48\">",
"      Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/49\">",
"      Boxer LA, Hutchinson R, Emerson S. Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia. Clin Immunol Immunopathol 1992; 62:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/50\">",
"      Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/51\">",
"      Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997; 34:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/52\">",
"      Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107:4628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/53\">",
"      Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000; 95:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/54\">",
"      Haurie C, Dale DC, Mackey MC. Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. Blood 1998; 92:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/55\">",
"      Horwitz M, Benson KF, Person RE, et al. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet 1999; 23:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/56\">",
"      Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program 2004; :63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/57\">",
"      Aprikyan AG, Liles WC, Rodger E, et al. Cyclic neutropenia: Proliferative and survival characteristics of bone marrow hematopoietic cells (abstract). Blood 1998; 92: 699a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/58\">",
"      Logue GL, Shastri KA, Laughlin M, et al. Idiopathic neutropenia: antineutrophil antibodies and clinical correlations. Am J Med 1991; 90:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/59\">",
"      Kalra R, Dale D, Freedman M, et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood 1995; 86:4579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/60\">",
"      Morikawa K, Oiwa K, Oseko F, et al. Distinct effect of G-CSF on the growth and differentiation of myeloid progenitor cells from chronic idiopathic neutropenia. Intern Med 1995; 34:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12680/abstract/61\">",
"      Heussner P, Haase D, Kanz L, et al. G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. Int J Hematol 1995; 62:225.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7098 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12680=[""].join("\n");
var outline_f12_24_12680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6190803\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INHERITED BONE MARROW FAILURE SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fanconi anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H868984\">",
"      Dyskeratosis congenita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diamond-Blackfan anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Amegakaryocytic thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Congenital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acquired",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Severe congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1013919\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic benign neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6190803\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7098|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_24_12681="Prenatal screening for genetic disease in the Ashkenazi Jewish population";
var content_f12_24_12681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12681/contributors\">",
"     Ashley S Roman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12681/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12681/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/24/12681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a mutant allele is introduced into a community that procreates mostly among themselves, the allele will develop a higher frequency in the community than in the general population. As a result, the community will be at increased risk of inheriting rare genetic disorders associated with the allele, a situation known as the founder effect.",
"   </p>",
"   <p>",
"    Ashkenazi Jews are descendants of Jews from Eastern Europe, while Sephardic Jews are descendants of Jews from Spain, Portugal, and North Africa. Individuals of Ashkenazi Jewish descent are an example of the founder effect. It is common for Ashkenazi Jews to carry genetic mutations for one of the diseases in a group of disorders termed \"Jewish genetic disorders.\" It is estimated that one in four to one in five individuals of Ashkenazi Jewish descent carry a mutation for one of these genetic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/1\">",
"     1",
"    </a>",
"    ]. In fact, for many of these genetic disorders, the mutation has only been identified in individuals of Ashkenazi Jewish heritage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/2\">",
"     2",
"    </a>",
"    ]. Most of these diseases are severe, untreatable, and associated with a shortened life expectancy.",
"   </p>",
"   <p>",
"    Carrier screening can identify an individual who possesses a gene that may increase the individual's risk of having a child with that particular disease. The increased risk occurs when two carriers conceive a child: each offspring has a 25 percent chance of inheriting both parents' alleles with the abnormal gene sequence. For this reason, genetic carrier screening programs have been successful and have a high acceptance rate among Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening programs should be voluntary, confidential, and with informed consent. Prior to implementing any screening program, several criteria should be met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The disease should pose a significant burden to the population",
"     </li>",
"     <li>",
"      A reliable means of diagnosis should exist",
"     </li>",
"     <li>",
"      The test should be cost-effective",
"     </li>",
"     <li>",
"      The capacity to alter clinical management should be available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening for Tay-Sachs disease is the paradigm for carrier screening programs (see",
"    <a class=\"local\" href=\"#H43\">",
"     'Tay-Sachs disease'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/4\">",
"     4",
"    </a>",
"    ]. Since carrier screening was initiated in the 1970s, the disease burden from Tay-Sachs has been reduced by 90 percent in the Ashkenazi Jewish population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/5\">",
"     5",
"    </a>",
"    ]. Success with Tay-Sachs screening programs led to development of sensitive, low cost carrier testing for several additional genetic diseases prevalent in this population (",
"    <a class=\"graphic graphic_table graphicRef80314 \" href=\"UTD.htm?35/19/36155\">",
"     table 1",
"    </a>",
"    ). There are no effective treatments for most of these disorders, the primary intervention is prevention of birth of an affected infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Candidates for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics and American College of Medical Genetics (ACMG) have published recommendations for prenatal and preconceptional screening of individuals of Ashkenazi Jewish heritage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The recommendations of each college differ slightly in qualifying how much heritage is necessary to offer testing and in the number of diseases for which carrier screening should be offered:",
"   </p>",
"   <p>",
"    (1) The personal and family history of individuals considering pregnancy, or who are already pregnant, should be reviewed to determine whether either member of the couple is of Ashkenazi Jewish ancestry or has a relative with one or more genetic disorders (",
"    <a class=\"graphic graphic_table graphicRef80314 \" href=\"UTD.htm?35/19/36155\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (2) Any patient of Eastern European or Ashkenazi Jewish descent, or who has a relative with one of the genetic conditions prevalent in the Ashkenazi Jewish population, should be offered carrier screening. The ACMG recommends that one grandparent of Ashkenazi Jewish descent is enough to offer testing. Additionally, if an individual is unsure of their exact heritage, the ACMG recommends offering testing.",
"   </p>",
"   <p>",
"    Patients with a first degree relative (parent, sibling, child) or second-degree relative",
"    <span class=\"nowrap\">",
"     (aunt/uncle,",
"    </span>",
"    <span class=\"nowrap\">",
"     niece/nephew,",
"    </span>",
"    grandparent, half-sibling) affected with a severe or lethal autosomal recessive disorder should be offered carrier screening because their risk of being a carrier is high. This risk ranges from 33 to 100 percent, depending upon which relative is affected.",
"   </p>",
"   <p>",
"    Whether to screen patients with a more remote family history of disease is controversial. As an example, a patient has a 1 in 16 chance of being a carrier if a fifth-degree relative (eg, second cousin) is known to have been affected with one of these autosomal recessive diseases, a risk that is still higher than the carrier frequencies of most of the genetic diseases in the Ashkenazi population. Therefore, we feel any history of a blood relative with one of these autosomal recessive disorders should initiate testing in an individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     What to screen for",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ACOG Committee on Genetics recommends that all Ashkenazi Jews should be offered carrier screening for four of the most common disorders that are either lethal or associated with significant morbidity: Tay-Sachs disease, Canavan disease, cystic fibrosis, and familial dysautonomia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]. Screening should be performed preconceptionally or during early pregnancy. Although Gaucher's disease is also relatively common with a carrier rate of",
"      <span class=\"nowrap\">",
"       1/15",
"      </span>",
"      and a disease rate of",
"      <span class=\"nowrap\">",
"       1/900,",
"      </span>",
"      it was not included among these diseases because its severity is variable (some cases are mild) and the age of onset is highly variable (ranging from few months to 90 years of age).",
"     </li>",
"     <li>",
"      The ACMG recommends that, in addition to these four disorders, carrier screening be offered routinely for five additional diseases: mucolipidosis IV, Niemann Pick disease type A, Fanconi anemia group C, Bloom Syndrome, and Gaucher disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/1\">",
"       1",
"      </a>",
"      ]. By comparison, ACOG suggests that only patients with a family member affected with one of these additional five diseases be offered screening for the relevant disease; however, the full panel of nine screening tests may be performed in those who specifically request them [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some centers offer a more expanded panel that includes carrier screening for other autosomal recessive disorders prevalent in the Ashkenazi Jewish population, including Maple Syrup Urine Disease and Glycogen Storage Disease Type 1a. The ACMG recommends that before carrier screening for a disorder is implemented, two criteria must be met:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    1 - The natural history of the disorder must be well-understood and associated with significant morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality.",
"   </p>",
"   <p>",
"    2 - The screening test should have greater than a 90 percent detection rate or the allele frequency should be more than or equal to 1 percent in the Ashkenazi Jewish population.",
"   </p>",
"   <p>",
"    Maple Syrup Urine Disease, dihydrolipoamide dehydrogenase deficiency, and Glycogen Storage Disease Type 1a meet both of these criteria. Therefore, it is reasonable to provide carrier screening for these disorders in addition to screening for the nine disorders recommended by the ACMG.",
"   </p>",
"   <p>",
"    Some genetic screening programs offer testing for other autosomal recessive diseases, however, these diseases do not have an allele frequency of &ge;1 percent in the Ashkenazi Jewish population. These inherited diseases (and allele frequencies) include Nemaline Myopathy (1 in 120), Usher Syndrome IF (1 in 165), Usher Syndrome Type III (1 in 107), Walker-Warburg Syndrome (1 in 120), and Joubert syndrome 2 (1 in 110). Testing for carrier status is indicated if a patient has a family member affected by one of these disorders or known to be a carrier of a gene responsible for one of these disorders, however, the value of routine population screening of Ashkenazi Jewish individuals for these disorders is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     When to screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, carrier testing of either partner of an Ashkenazi Jewish couple is initiated at a preconceptional counseling visit. If that partner tests positive as a carrier of a known genetic mutation, carrier testing can then be extended to the other partner.",
"   </p>",
"   <p>",
"    If the woman is already pregnant, carrier testing of both partners is usually performed simultaneously at the first prenatal visit. This should allow ample time for further prenatal evaluation and diagnosis in the event that both partners screen positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Test requisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent prior to carrier screening is required.",
"   </p>",
"   <p>",
"    Carrier testing for each disease generally involves DNA mutation analysis for that disease. There are many different mutations for the various diseases; thus, the test requisition typically states \"DNA mutation analysis for\" and then lists the diseases the patient has consented to be screened for (eg, Tay-Sachs, Bloom Syndrome, cystic fibrosis, etc) rather than a specific mutation. At many laboratories, carrier screening is available as part of a panel of 4, 9, 11, or more diseases. If testing for a panel of diseases is ordered, the patient should have consented to testing for all of the diseases in the panel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mixed ancestry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for known mutations has variable sensitivity and specificity in the setting of mixed ancestry. Frequencies of disease and known mutations are less well established, and detection rates of non-Ashkenazi Jewish carriers are lower. It is prudent to offer testing with these limitations discussed if there appears to be any Ashkenazi Jewish ancestry.",
"   </p>",
"   <p>",
"    An exception is cystic fibrosis, a disease for which carrier detection rates and carrier frequencies are known across different ethnic and racial groups. In addition, for Tay Sachs, biochemical screening is recommended as a first-line for carrier testing in non-Jewish individuals or individuals of mixed ethnicity; it has a high detection rate regardless of ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Only one partner has Ashkenazi background",
"    </span>",
"    &nbsp;&mdash;&nbsp;When only one partner is of Ashkenazi Jewish heritage, that partner should be tested for known mutations first. A stepwise approach is advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    1 - The Ashkenazi Jewish partner should be tested first with DNA-mutation analysis for the disease(s) of interest. If there is a family history of an affected relative and a specific mutation has been identified in the family, then DNA analysis should also be performed for that particular mutation.",
"   </p>",
"   <p>",
"    2 - If testing is positive, genetic counseling should be offered to both partners.",
"   </p>",
"   <p>",
"    3 - DNA-based and biochemical carrier testing should be extended to the non-Jewish partner. Although DNA mutation analysis has a lower sensitivity in the non-Ashkenazi Jewish population, biochemical testing of carriers for many of the diseases (eg, Gaucher disease, Tay-Sachs disease) can detect carriers with unrecognized mutations.",
"   </p>",
"   <p>",
"    4 - If the Ashkenazi Jewish partner tests positive for a particular mutation and the non-Jewish partner tests negative, genetic counseling should be provided regarding residual risk.",
"   </p>",
"   <p>",
"    5 - When mutations are identified in both parents, prenatal diagnostic testing (eg, amniocentesis or chorionic villus sampling) with DNA analysis should be offered. If neither parent carries a known mutation, but both have been determined to be carriers via biochemical testing (as in the case of Tay Sachs, Gaucher or Canavan Disease), prenatal testing can be performed by alternative testing (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling should be provided to all prospective Ashkenazi Jewish parents, and should include risk of disease, disease manifestations, range of severity, and management options. A negative screening test result for one or both partners significantly reduces the possibility of an affected offspring, but does not exclude it, because test sensitivity is less than 100 percent, therefore not every carrier is identified.",
"   </p>",
"   <p>",
"    If carrier status of both parents is confirmed, each offspring has a 25 percent chance of inheriting the disease, a 50 percent chance of being a carrier, and 25 percent chance of not inheriting the affected allele. Once carrier mutations have been identified in both parents, the couple have multiple options if they choose to prevent the birth of an affected infant. They may avoid pregnancy, use gametes from a donor who is a noncarrier, or employ preimplantation genetic diagnosis with implantation of only unaffected embryos. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If pregnancy is already established, DNA testing can be performed on chorionic villi or amniocytes to determine fetal status. Pregnancy termination is an option, if desired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an individual is found to be a carrier,",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    relatives are also at risk for carrying the same mutation; thus, the individual should be encouraged to discuss this information with them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BLOOM SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloom syndrome is an autosomal recessive chromosomal instability disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome is extremely rare in the general population. In the Ashkenazi Jewish population, however, the carrier frequency is",
"    <span class=\"nowrap\">",
"     1/102",
"    </span>",
"    and the disease incidence is",
"    <span class=\"nowrap\">",
"     1/48,000",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. One-third of affected individuals are of Ashkenazi Jewish heritage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of Bloom syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small stature",
"     </li>",
"     <li>",
"      Predisposition to the early development of a wide variety of cancers",
"     </li>",
"     <li>",
"      Facial anomalies and sun-sensitive facial erythema",
"     </li>",
"     <li>",
"      Infertility",
"     </li>",
"     <li>",
"      Immunodeficiency",
"     </li>",
"     <li>",
"      Restricted intellectual ability",
"     </li>",
"     <li>",
"      Predisposition to develop late-onset non-insulin dependent diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features are believed to be the result of increased chromosome breakage and sister chromatid exchange. The mean age of death in patients with Bloom syndrome is 28 years (range 4 to 46 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/13\">",
"     13",
"    </a>",
"    ]. The cause of death is usually cancer, commonly leukemia or a malignancy of gastrointestinal origin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=see_link\">",
"     \"Bloom syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Ashkenazi Jewish population, almost all patients with Bloom syndrome are homozygous for a complex frameshift mutation (6-bp",
"    <span class=\"nowrap\">",
"     deletion/7-bp",
"    </span>",
"    insertion at BLM nucleotide 2281) blmAsh. Carrier testing for this mutation is estimated to detect 95 to 97 percent of carriers in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CANAVAN DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Canavan disease is a neurodegenerative disease characterized by leukodystrophy and spongy degeneration of the brain. It is caused by an enzyme deficiency aspartoacylase (ASPA), which leads to increased N-acetylaspartic acid (NAA) levels in brain and urine. NAA is an amino acid normally abundant in the brain and is second only to glutamate in the free amino acid pool [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/14\">",
"     14",
"    </a>",
"    ]. Its role is unclear, but NAA may be involved in myelin synthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;One in 40 Ashkenazi Jewish individuals is a carrier of Canavan disease. The incidence of disease in this population is",
"    <span class=\"nowrap\">",
"     1/3000",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/6000",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with Canavan disease appear normal at birth, but after a few months, they fail to meet developmental milestones. Hypotonic with poor head control are early findings. After six months of age, head size increases and macrocephaly develops due to storage of NAA. Ultimately, affected children are unable to sit, walk, or talk and become spastic. Sleep disturbances, optic atrophy with blindness, feeding difficulties, and gastroesophageal reflux are also characteristic of the disease. Most children die within the first years of life, although survival to the second decade can be achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for Canavan disease was cloned in 1993. Mutation analysis for two mutations of this gene can detect 98 percent of carriers in the Ashkenazi Jewish population. As with many of the genetic diseases seen in the Ashkenazi Jewish population, it is difficult to screen for Canavan disease in non-Jews due to its rarity and more diversity in mutations.",
"   </p>",
"   <p>",
"    Several other techniques have been employed to detect affected fetuses or infants. An enzyme assay using cultured skin fibroblasts can be used to determine ASPA activity. This enzyme assay, however, cannot be performed on amniocytes, chorionic villi, or blood due to normally low activity levels in these tissues, thus limiting its use in prenatal diagnosis.",
"   </p>",
"   <p>",
"    An analyte assay assessing levels of NAA can be performed on amniotic fluid or urine with the caveat that NAA levels in amniotic fluid are normally lower than those found in urine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The ACMG recommends that if known mutations cannot be identified for either parent, but both parents are suspected to be carriers based on biochemical analysis, prenatal diagnosis via amniocentesis should be offered between 16 and 18 weeks of gestation to determine the concentration of NAA in amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CYSTIC FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is a chronic, progressive pulmonary and exocrine pancreatic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Ashkenazi Jews, the carrier frequency is",
"    <span class=\"nowrap\">",
"     1/19",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/29",
"    </span>",
"    and the incidence of disease is",
"    <span class=\"nowrap\">",
"     1/3300",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;CF typically involves the respiratory and gastrointestinal tracts and is characterized by chronic lung disease, recurrent pneumonia, pancreatic insufficiency, malabsorption, and diabetes mellitus. The clinical course is variable. In two-thirds of cases, the diagnosis is made in first year of life. More severe disease tends to present at an earlier age than milder disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for CFTR was located in 1989; since then, hundreds of mutations have been identified. The frequencies of disease-causing mutations vary among different ethnic groups and geographical regions. In the Ashkenazi Jewish population, mutation analysis for five mutations identifies 96 to 97 percent of the carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/21\">",
"     21",
"    </a>",
"    ]. Most laboratories screen for the 23 to 32 mutations that account for the vast majority of cystic fibrosis cases.",
"   </p>",
"   <p>",
"    Since CF carrier detection rates and carrier frequencies are known across different ethnic and racial groups, screening for this disorder is offered to couples in addition to the Ashkenazi Jewish population. Complete analysis of the CFTR gene can be performed via DNA sequencing, but is not appropriate for routine carrier screening, as the results may be difficult to interpret [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/22\">",
"     22",
"    </a>",
"    ]. Carrier screening and indications for CFTR gene sequencing are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=see_link\">",
"     \"Cystic fibrosis: Prenatal genetic screening\"",
"    </a>",
"    .) All patients who have CFTR gene sequencing should have a consultation with a genetics professional.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FAMILIAL DYSAUTONOMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial dysautonomia, also known as Riley-Day syndrome, is an autosomal recessive disease characterized by a progressive sensorimotor neuropathy, but sympathetic autonomic dysfunction is responsible for most clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all cases of familial dysautonomia have been reported in the Ashkenazi Jewish population. In this population, carrier frequency is",
"    <span class=\"nowrap\">",
"     1/32,",
"    </span>",
"    but may be as high as",
"    <span class=\"nowrap\">",
"     1/18",
"    </span>",
"    in Ashkenazi Jews of Polish descent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Disease incidence is",
"    <span class=\"nowrap\">",
"     1/3700",
"    </span>",
"    Ashkenazi Jews in Israel [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations are evident at birth with feeding difficulties and hypotonia. Infants have significant gastroesophageal reflux with aspiration and chronic lung disease. Affected individuals have decreased pain and temperature perception. Autonomic dysfunction includes the absence of tears, severe episodes of nausea and vomiting, and rapid swings in blood pressure from severe hypertension to postural hypotension. Intelligence is usually normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;One major mutation accounts for 99.5 percent of mutations in the Ashkenazi Jewish population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/27\">",
"     27",
"    </a>",
"    ]. DNA mutation analysis is available for carrier testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     FANCONI ANEMIA TYPE C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fanconi's anemia is an autosomal recessive disorder characterized by several congenital anomalies (",
"    <a class=\"graphic graphic_table graphicRef71159 \" href=\"UTD.htm?14/12/14540\">",
"     table 2",
"    </a>",
"    ), progressive bone marrow failure, and a higher prevalence of malignancies. It appears to result from increased chromosomal breakage and increased sensitivity to DNA cross-linking agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carrier frequency of Fanconi anemia type C is",
"    <span class=\"nowrap\">",
"     1/89",
"    </span>",
"    in the Ashkenazi Jewish population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/28\">",
"     28",
"    </a>",
"    ], compared with",
"    <span class=\"nowrap\">",
"     1/300",
"    </span>",
"    in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Disease incidence in the Ashkenazi Jewish population is",
"    <span class=\"nowrap\">",
"     1/32,000.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fanconi's",
"    anemia is associated with congenital anomalies affecting multiple organ systems with variable frequency. Affected individuals may have cafe au lait spots, absent thumbs, radial hypoplasia, scoliosis, horseshoe kidneys, and gastrointestinal, cardiac, or neurological abnormalities. Neonates typically appear normal and have normal blood counts. Pancytopenia develops gradually in 90 percent of patients with a median age of onset of six to nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, approximately 4 percent of cases are recognized between birth and one year of age. The platelet count and hemoglobin are the first to decline, followed by the granulocytes. There is significant clinical variability in the disease, even within families. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Death usually results from hemorrhage or infection. The median survival is between age 16 and 23 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/33\">",
"     33",
"    </a>",
"    ]. The disease is also associated with an increased risk of leukemia and other cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike several of the other genetic diseases in the Ashkenazi Jewish population, the pancytopenia associated with Fanconi's anemia can be treated with stem-cell transplantation. When HLA-identical sibling donors are used, survival is 70 percent at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/34\">",
"     34",
"    </a>",
"    ]. Although survival may be improved with transplantation, many of these patients ultimately go on to develop cancers due to chromosomal fragility and toxicity associated with pretransplantation conditioning regimens which often include the use of radiation and chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link&amp;anchor=H9#H9\">",
"     \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eight mutations responsible for Fanconi anemia have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. In the general population, the disease has a carrier rate of 1 in 300. A single mutation in complementation group FA-C (FANCC) is unique to FA patients in the Ashkenazi Jewish population and has a carrier frequency of",
"    <span class=\"nowrap\">",
"     1/89",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/28\">",
"     28",
"    </a>",
"    ]. Mutation analysis is available for carrier testing for this specific mutation. Two other mutations are unique to Ashkenazi Jews, but with a much lower frequency, and thus do not merit carrier screening at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     GAUCHER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease is a lysosomal storage disease caused by a deficiency of the enzyme glucocerebrosidase, which results in a reduced ability to degrade glucosylceramide. Consequently, glucosylceramide accumulates in macrophages of the reticuloendothelial system in the liver, spleen, bone marrow, and lungs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease is the most prevalent genetic disorder among Ashkenazi Jews. The incidence of the disease in this population is",
"    <span class=\"nowrap\">",
"     1/900,",
"    </span>",
"    and two-thirds of affected individuals are Ashkenazi Jews. The carrier rate in the Ashkenazi Jewish population is",
"    <span class=\"nowrap\">",
"     1/15,",
"    </span>",
"    compared to",
"    <span class=\"nowrap\">",
"     1/100",
"    </span>",
"    in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease is characterized by bone pain and fractures, thrombocytopenia, and hepatosplenomegaly. Onset of symptoms can occur at any time from infancy onward, but 50 percent of patients do not present until after 45 years of age. Some cases are mild or asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 100 mutant alleles responsible for Gaucher disease have been identified, but seven account for more than 96 percent of disease alleles in the Ashkenazi Jewish population. Mutation analysis for these alleles can detect 97 percent of carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/21,40-42\">",
"     21,40-42",
"    </a>",
"    ] and enzyme activity assays can help detect carriers who do not have one of these alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/43\">",
"     43",
"    </a>",
"    ]. In 80 percent of carriers for Gaucher disease, enzyme activity is 50 percent of normal. In the non-Ashkenazi Jewish population, the addition of enzyme activity testing can increase the sensitivity of testing, which is 74 percent with DNA testing alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If both parents carry a known mutation for Gaucher disease, prenatal diagnosis involving DNA testing of fetal cells obtained via amniocentesis or chorionic villus sampling should be offered. If both parents have been identified as carriers, but one or both do not carry a known mutation, prenatal diagnosis can be achieved by testing enzyme activity in amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     MUCOLIPIDOSIS TYPE IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disease. The disease is caused by accumulation of lipids and mucopolysaccharides in cell lysosomes due to abnormal endocytosis of normal membrane components. Unlike several of the other genetic diseases prevalent in the Ashkenazi Jewish population, no single aberrant protein has been identified as the cause of the disease. Mutation analysis has mapped the location of the mutation to a gene that encodes mucolipin 1, a membrane protein with unknown function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 100 cases of MLIV have been reported. Eighty percent of these cases have occurred in the Ashkenazi Jewish population. Carrier frequency is",
"    <span class=\"nowrap\">",
"     1/100",
"    </span>",
"    and disease incidence is",
"    <span class=\"nowrap\">",
"     1/40,000",
"    </span>",
"    among Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;MLIV is a progressive neurologic disorder characterized by physical and developmental delays, severe intellectual disability, corneal clouding, and retinal degeneration. Most affected individuals are diagnosed by age two to three years and never attain language skills or motor function beyond those of a one- to two-year-old. Patients with MLIV can have normal life spans, although life expectancy is poorly characterized due to the rarity of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carrier screening is available for the two genes that account for more than 95 percent of mutant alleles in the Ashkenazi Jewish population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. A third mutation has also been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     NIEMANN-PICK DISEASE TYPE A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niemann-Pick disease type A (NPDA) is an autosomal recessive, lysosomal storage disorder. The disease is caused by a deficiency of acid sphingomyelinase, which results in accumulation of sphingomyelin in cell lysosomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=see_link\">",
"     \"Overview of Niemann-Pick disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Ashkenazi Jewish population, carrier frequency is cited as",
"    <span class=\"nowrap\">",
"     1/70",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/90",
"    </span>",
"    and disease incidence is cited as",
"    <span class=\"nowrap\">",
"     1/25,600",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/32,000",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants appear normal at birth. Affected patients present with hepatosplenomegaly, feeding difficulties and loss of early motor skills in the first few months of life. Rapid, progressive, and profound loss of neurologic function leading to death occurs by two to three years of age. A peripheral neuropathy is manifest as hypotonia and absent reflexes and macular cherry red spots can be seen on fundoscopic examination in approximately 50 percent of patients. There is no known treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=see_link\">",
"     \"Overview of Niemann-Pick disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three mutations associated with NPDA are responsible for more than 95 percent of cases in Ashkenazi Jews. Carrier screening with DNA analysis is available for these mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     TAY-SACHS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tay-Sachs disease is an autosomal recessive, neurodegenerative disease caused by excess storage of the cell membrane glycolipid, Gm2 ganglioside, within cell lysosomes. This Gm2 gangliosidosis is caused by a deficiency in beta-Hexosaminidase A (Hex A).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Ashkenazi Jewish population, carrier frequency is",
"    <span class=\"nowrap\">",
"     1/25",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/30",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/21\">",
"     21",
"    </a>",
"    ], and disease incidence is",
"    <span class=\"nowrap\">",
"     1/3600",
"    </span>",
"    compared to",
"    <span class=\"nowrap\">",
"     1/360,000",
"    </span>",
"    in other populations. Tay-Sachs disease is also relatively more common in individuals of Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent. Because of screening protocols initiated in the 1970s targeting Ashkenazi Jews, the number of cases of Tay-Sachs disease detected prenatally in the non-Jewish population has increased three- to four-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease is characterized by normal motor development in the first few months of life. At two to six months of age, infants develop progressive weakness and loss of motor skills with hypotonia, hyperreflexia, and characteristic cherry red macula. Infants are commonly macrocephalic from accumulation of storage material in the brain. Ultimately, patients develop seizures, blindness, and spasticity. The life expectancy is two to five years, with death in most cases from pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing identifies 99.9 percent of carriers in the Ashkenazi Jewish population, with a false negative rate of less than 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/21,47\">",
"     21,47",
"    </a>",
"    ]. Two forms of testing for the carrier state exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DNA analysis &mdash; Three mutations in Ashkenazi Jews appear to be responsible for the vast majority of cases. Ashkenazi Jewish carrier testing should start with DNA mutation analysis. Non-Jews should also be tested for a fourth mutation, which accounts for 15 percent of mutations in this population.",
"     </li>",
"     <li>",
"      Enzyme analysis &mdash; Enzyme assays can measure activity of Hex A and Hex B in serum or leukocytes. Tay-Sachs disease carriers have decreased Hex A activity and normal or increased activity of Hex B. Enzyme analysis can also be performed on amniocytes or chorionic villus cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the test has several limitations. First, there may be overlap in carrier and non-carrier range, making the test inconclusive in some cases. The test also can be unreliable in pregnant patients and in women on hormonal forms of contraception. In these instances, serum levels of Hex A can be falsely elevated, increasing the likelihood of false negative screening test results (a positive test is a low level of hex A). If biochemical screening is performed in pregnant women or women taking oral contraceptives, leukocytes must be used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/4\">",
"     4",
"    </a>",
"    ]. Carriers of pseudodeficiency alleles, alleles that are associated with decreased Hex A activity, but are not associated with the disease, also cannot be distinguished from carriers of true mutations with biochemical testing.",
"   </p>",
"   <p>",
"    For these reasons, DNA testing should be performed first in patients of Ashkenazi Jewish descent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/47\">",
"     47",
"    </a>",
"    ], but biochemical analysis should be used for non-Jewish individuals or individuals with mixed ancestry (fewer than four Ashkenazi Jewish grandparents) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Ambiguous or positive screening results should be confirmed by DNA analysis for the most common mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal diagnosis &mdash; If both parents are carriers of known mutations, prenatal invasive testing via amniocentesis or chorionic villus sampling with DNA-based testing for the identified mutations should be offered. When both parents are known to be carriers, but one or both do not carry a known mutation, fetal cells obtained via amniocentesis or chorionic villus sampling should be tested for Hex A enzymatic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12681/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least one in five Ashkenazi Jews is a carrier of a genetic mutation for one of the diseases in a group of disorders termed \"Jewish Genetic Disorders.\" For many of these genetic disorders, the mutation has only been identified in individuals of Ashkenazi Jewish heritage. Most of these diseases are severe, untreatable, and associated with a shortened life expectancy. Carrier testing can often identify individuals at risk. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The personal and family history of individuals considering pregnancy, or who are already pregnant, should be reviewed to determine whether either member of the couple is of Ashkenazi Jewish ancestry or has a relative with one or more genetic disorders (",
"      <a class=\"graphic graphic_table graphicRef80314 \" href=\"UTD.htm?35/19/36155\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidates for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend offering carrier screening for the nine inherited disorders to patients of Eastern European or Ashkenazi Jewish descent, defined as any individual with one grandparent with known Ashkenazi Jewish heritage, or those who have a relative with one of the genetic conditions prevalent in the Ashkenazi Jewish population (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If an individual is unsure of their precise heritage, carrier screening is still recommended. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidates for screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/1\">",
"      Gross SJ, Pletcher BA, Monaghan KG, Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008; 10:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/2\">",
"      Eng CM, Schechter C, Robinowitz J, et al. Prenatal genetic carrier testing using triple disease screening. JAMA 1997; 278:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/3\">",
"      Kronn D, Jansen V, Ostrer H. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY. Arch Intern Med 1998; 158:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/4\">",
"      ACOG Committee on Genetics. ACOG committee opinion. Number 318, October 2005. Screening for Tay-Sachs disease. Obstet Gynecol 2005; 106:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/5\">",
"      Kaback M, Lim-Steele J, Dabholkar D, et al. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA 1993; 270:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/6\">",
"      ACOG committee opinion. Number 442. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2009; 114:950.",
"     </a>",
"    </li>",
"    <li>",
"     www.geneticdiseasefoundation.org (accessed May 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/8\">",
"      Monaghan KG, Feldman GL, Palomaki GE, et al. Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. Genet Med 2008; 10:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/9\">",
"      Wallerstein R, Starkman A, Jansen V. Carrier screening for Gaucher disease in couples of mixed ethnicity. Genet Test 2001; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/10\">",
"      Shahrabani-Gargir L, Shomrat R, Yaron Y, et al. High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. Genet Test 1998; 2:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/11\">",
"      Li L, Eng C, Desnick RJ, et al. Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Mol Genet Metab 1998; 64:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/12\">",
"      Roa BB, Savino CV, Richards CS. Ashkenazi Jewish population frequency of the Bloom syndrome gene 2281 delta 6ins7 mutation. Genet Test 1999; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     German, J. Bloom's syndrome: Incidence, age of onset, and types of leukemia in the Bloom's Syndrome Registry. In: Bartsocas, CS, Loukopoulos, D. Genetics of Hematological Disorders, Hemisphere Publishers, Washington, DC 1992. p. 241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/14\">",
"      TALLAN HH, MOORE S, STEIN WH. N-Acetyl-L-aspartic acid in brain. J Biol Chem 1956; 219:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/15\">",
"      Kronn D, Oddoux C, Phillips J, Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995; 57:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/16\">",
"      Matalon RM, Michals-Matalon K. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Front Biosci 2000; 5:D307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/17\">",
"      Sugarman, EA, Allitto, BA. Carrier testing for seven diseases common in the Ashkenazi Jewish population, implications for counseling and testing. Obstet Gynecol 2001; 97:S38-9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/18\">",
"      Matalon R, Michals K, Sebesta D, et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/19\">",
"      Adachi M, Torii J, Schneck L, Volk BW. Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Bertrans type). Acta Neuropathol 1972; 20:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/20\">",
"      Abeliovich D, Lavon IP, Lerer I, et al. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet 1992; 51:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/21\">",
"      Eng, CM, Burgert, TS, Schecter, C, et al. Multiplex genetic testing in the Ashkenazi Jewish population. Am J Hum Genet 1995; 57:A57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/22\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet Gynecol 2011; 117:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/23\">",
"      Leib JR, Gollust SE, Hull SC, Wilfond BS. Carrier screening panels for Ashkenazi Jews: is more better? Genet Med 2005; 7:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/24\">",
"      Lehavi O, Aizenstein O, Bercovich D, et al. Screening for familial dysautonomia in Israel: evidence for higher carrier rate among Polish Ashkenazi Jews. Genet Test 2003; 7:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/25\">",
"      Maayan C, Kaplan E, Shachar S, et al. Incidence of familial dysautonomia in Israel 1977-1981. Clin Genet 1987; 32:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/26\">",
"      Blumenfeld A, Slaugenhaupt SA, Liebert CB, et al. Precise genetic mapping and haplotype analysis of the familial dysautonomia gene on human chromosome 9q31. Am J Hum Genet 1999; 64:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/27\">",
"      Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 2001; 68:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/28\">",
"      Verlander PC, Kaporis A, Liu Q, et al. Carrier frequency of the IVS4 + 4 A--&gt;T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood 1995; 86:4034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/29\">",
"      Swift M. Fanconi's anaemia in the genetics of neoplasia. Nature 1971; 230:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/30\">",
"      Schroeder TM, Tilgen D, Kr&uuml;ger J, Vogel F. Formal genetics of Fanconi's anemia. Hum Genet 1976; 32:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/31\">",
"      Gordon-Smith EC, Rutherford TR. Fanconi anaemia--constitutional, familial aplastic anaemia. Baillieres Clin Haematol 1989; 2:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/32\">",
"      Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101:1249.",
"     </a>",
"    </li>",
"    <li>",
"     Auerbach, AD, Buchwald M, Joenje H. Fanconi anemia. In: The Genetic Basis of Human Cancer. In: Vogelstein, B, Kinzler, KW (Eds), McGraw Hill, New York 1998. p. 317.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/34\">",
"      Guardiola P, Soci&eacute; G, Pasquini R, et al. Allogeneic stem cell transplantation for Fanconi Anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21 Suppl 2:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/35\">",
"      Grompe M, D'Andrea A. Fanconi anemia and DNA repair. Hum Mol Genet 2001; 10:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/36\">",
"      Levran O, Erlich T, Magdalena N, et al. Sequence variation in the Fanconi anemia gene FAA. Proc Natl Acad Sci U S A 1997; 94:13051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/37\">",
"      Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/38\">",
"      Zuckerman S, Lahad A, Shmueli A, et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA 2007; 298:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/39\">",
"      Beutler E. Carrier screening for Gaucher disease: more harm than good? JAMA 2007; 298:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/40\">",
"      Beutler E, Gelbart T, Kuhl W, et al. Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. Proc Natl Acad Sci U S A 1991; 88:10544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/41\">",
"      Horowitz M, Tzuri G, Eyal N, et al. Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am J Hum Genet 1993; 53:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/42\">",
"      Tsusi, S, Martin, BM, Barranger, JA, Stubblefield BK, Lamarca ME, Ginns EI. Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci USA 1988; 85:2349.",
"     </a>",
"    </li>",
"    <li>",
"     Barranger, JA, Ginns, EI. Glucosylcerimidelipidoses: Gaucher disease. In: The metabolic basis of inherited disease, 6th ed, Scriver, CR, Beaudet, AL, Sly, WS, Valle, D (Eds), McGraw-Hill 1989 p. 1677.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/44\">",
"      Bassi MT, Manzoni M, Monti E, et al. Cloning of the gene encoding a novel integral membrane protein, mucolipidin-and identification of the two major founder mutations causing mucolipidosis type IV. Am J Hum Genet 2000; 67:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/45\">",
"      Bargal R, Avidan N, Olender T, et al. Mucolipidosis type IV: novel MCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population. Hum Mutat 2001; 17:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/46\">",
"      Slaugenhaupt SA, Acierno JS Jr, Helbling LA, et al. Mapping of the mucolipidosis type IV gene to chromosome 19p and definition of founder haplotypes. Am J Hum Genet 1999; 65:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12681/abstract/47\">",
"      Bach G, Tomczak J, Risch N, Ekstein J. Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am J Med Genet 2001; 99:70.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 428 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12681=[""].join("\n");
var outline_f12_24_12681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H47\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Candidates for screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      What to screen for",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      When to screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Test requisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mixed ancestry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Only one partner has Ashkenazi background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BLOOM SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CANAVAN DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CYSTIC FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FAMILIAL DYSAUTONOMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      FANCONI ANEMIA TYPE C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      GAUCHER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      MUCOLIPIDOSIS TYPE IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      NIEMANN-PICK DISEASE TYPE A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      TAY-SACHS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/428|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/19/36155\" title=\"table 1\">",
"      Genetic diseases with increased frequency in Ashkenazi Jews",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14540\" title=\"table 2\">",
"      Malformations Fanconi anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=related_link\">",
"      Bloom syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=related_link\">",
"      Cystic fibrosis: Prenatal genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=related_link\">",
"      Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=related_link\">",
"      Overview of Niemann-Pick disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_24_12682="Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials";
var content_f12_24_12682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12682/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12682/contributors\">",
"     Kapil Kumar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12682/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12682/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/24/12682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/24/12682/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/24/12682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term outcomes, such as survival or rate of thromboembolism, are similar with either rhythm or rate control strategies in patients with atrial fibrillation (AF) (",
"    <a class=\"graphic graphic_figure graphicRef61608 \" href=\"UTD.htm?19/25/19870\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74434 \" href=\"UTD.htm?8/51/9022\">",
"     figure 2",
"    </a>",
"    ). In addition, anticoagulation is required with both in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, the main goal of therapy is to reduce symptoms by decreasing the frequency and duration of episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the rhythm control strategy is chosen, the recommended drugs for maintenance of sinus rhythm vary with the clinical setting (",
"    <a class=\"graphic graphic_table graphicRef78424 \" href=\"UTD.htm?25/39/26236\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef83173 \" href=\"UTD.htm?35/57/36766\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Optimal antiarrhythmic drug therapy should be both effective and have a low incidence of toxicity, including proarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients for whom rhythm control is chosen will require rate control, both prior to its initiation and after, as many patients will have breakthrough episodes of AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The studies describing the efficacy and toxicity (including proarrhythmia) of the different antiarrhythmic drugs used to maintain sinus rhythm in patients with AF will be reviewed here. Recommendations concerning the use of pharmacologic therapy, the choice between a rhythm and a rate control strategy, and the role of alternative methods to maintain sinus rhythm in selected patients who are refractory to conventional therapy, including surgery and radiofrequency ablation, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will also address the issue of whether other medications are associated with a decreased frequency of recurrent AF. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Other therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYSTEMATIC REVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of a number of antiarrhythmic drugs were assessed in a systematic review, which included 44 trials in which an antiarrhythmic drug for the treatment of AF was compared against a placebo, another antiarrhythmic, or untreated controls, with at least six months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/9\">",
"     9",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to placebo, class IA, class IC, and class III drugs (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 2",
"      </a>",
"      ) all lowered the recurrence rate of AF, with odds ratios of 0.51, 0.36, and 0.37, respectively.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      was the most effective antiarrhythmic, with odds ratios of 0.19, 0.31 and 0.43 compared to untreated controls, class I drugs, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , respectively.",
"     </li>",
"     <li>",
"      Withdrawals due to adverse effects were higher with all antiarrhythmic drugs compared to placebo.",
"     </li>",
"     <li>",
"      Class IA drugs were associated with increased mortality (odds ratio 2.39). Other antiarrhythmic drugs had a neutral effect on mortality.",
"     </li>",
"     <li>",
"      All antiarrhythmics except for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      had a proarrhythmic effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the general observation, as summarized in the following sections, that antiarrhythmics can reduce AF recurrences, but their overall value is limited by adverse effects. Virtually all of the antiarrhythmic drugs used to maintain sinus rhythm are proarrhythmic.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is an exception in this regard, in that it has a low proarrhythmic profile, but its many potential adverse effects and toxicities are problematic.",
"   </p>",
"   <p>",
"    It is important to note that this systematic review was written prior to the publication of the ATHENA trial with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    , which also has a very low proarrhythmic risk, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , but is not as effective as amiodarone in maintaining sinus rhythm. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Dronedarone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASS IA ANTIARRHYTHMIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    are class IA antiarrhythmic drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 2",
"    </a>",
"    ). These drugs act by modifying the sodium channel and inhibiting the outward potassium current resulting in QT prolongation. They also have important vagolytic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    is the most widely studied class IA agent for the maintenance of sinus rhythm in AF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Although studies have shown that quinidine can reduce the rate of recurrent AF compared to placebo, it is associated with an increase in mortality, particularly in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/7,8,12,13\">",
"     7,8,12,13",
"    </a>",
"    ]. The use of quinidine for the maintenance of sinus rhythm has declined largely because other drugs are both more effective and safer.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     Disopyramide",
"    </a>",
"    also seems to have some benefit in the prevention of recurrent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/14\">",
"     14",
"    </a>",
"    ], although it must be used with caution since it can significantly worsen underlying heart failure.",
"   </p>",
"   <p>",
"    The efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    has been evaluated in older and poorly controlled trials or in patients who recently underwent coronary artery bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Oral procainamide is not readily available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLASS IC ANTIARRHYTHMIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    are classified as class IC antiarrhythmic agents, although they are known to have significantly different electrophysiologic and other properties. The following observations have been made regarding their efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to placebo, both are more effective in maintaining sinus rhythm at six months and in prolonging the time to AF recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/18-26\">",
"       18-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      appear to have equal efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. In a randomized, open-label study of 200 patients, for example, the probability of a safe and effective response (maintenance of sinus rhythm or fewer episodes of paroxysmal AF) at one year was 77 and 75 percent with flecainide and propafenone, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis evaluated trials of patients with AF resistant to class I drugs or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      after cardioversion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/29\">",
"       29",
"      </a>",
"      ]. Maintenance of sinus rhythm at 12 months was significantly more likely with amiodarone (60 versus 34 percent with flecainide).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the apparent benefit for the prevention of recurrent AF, the toxicity associated with these drugs has restricted their use. The cardiac complications of the class IC drugs include worsening of heart failure, bradycardia, and presumably drug-induced atrial and ventricular arrhythmias in 7 to 27 percent of cases. In up to 13 percent of patients AF recurs as, or converts to, persistent atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/30\">",
"     30",
"    </a>",
"    ]. Radiofrequency ablation of the atrial flutter, with continuation of the antiarrhythmic agent, is an effective approach for reducing arrhythmia recurrence and duration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Hybrid therapy in patients who develop atrial flutter'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    is restricted to those patients who have no structural heart disease, particularly coronary heart disease. The concern about the use of the class IC agents is primarily the result of the Cardiac Arrhythmia Suppression Trial (CAST), which showed that flecainide increased the number of deaths among patients with drug-suppressible ventricular premature beats in the year following a myocardial infarction (",
"    <a class=\"graphic graphic_figure graphicRef59975 \" href=\"UTD.htm?19/4/19534\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/32\">",
"     32",
"    </a>",
"    ]. It is not known if these findings can be extrapolated to other types of heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of nonsustained ventricular tachycardia\", section on 'Class I agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     Propafenone",
"    </a>",
"    has some mild beta-blocking activity in addition to its effects on the sodium channel. Thus, its toxicity may not be identical to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and, in patients with ventricular arrhythmia, propafenone appears to be less proarrhythmic. In a study of 480 patients with supraventricular arrhythmia treated with propafenone for 14 months, 59 percent of patients experienced at least one side effect; the drug was discontinued due to an adverse reaction in only 15 percent, while 17 percent required a reduction in dose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/33\">",
"     33",
"    </a>",
"    ]. Arrhythmia aggravation occurred in 2 percent of patients; the incidence was higher in those with structural heart disease compared to those without (3 versus 1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLASS III ANTIARRHYTHMIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    are classified as class III antiarrhythmic agents. There are, however, many dissimilarities among these drugs, and they should be considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is the most effective antiarrhythmic drug for the prevention of AF, as demonstrated in the following randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/34-39\">",
"     34-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Canadian Trial of Atrial Fibrillation (CTAF) randomly assigned 403 patients who had at least one episode of AF within six months of entry to low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/34\">",
"       34",
"      </a>",
"      ]. After a mean follow-up of 16 months, amiodarone was associated with a significantly greater likelihood of being free from recurrent AF (65 versus 37 percent for sotalol and propafenone) and a longer median time to recurrence (&gt;468 versus 98 days) (",
"      <a class=\"graphic graphic_figure graphicRef69285 \" href=\"UTD.htm?4/48/4878\">",
"       figure 4",
"      </a>",
"      ). There was no difference among the three therapies in mortality, but there was an almost significant trend toward an increased incidence of side effects resulting in drug discontinuation with amiodarone (18 versus 11 percent for sotalol or propafenone). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similar relative efficacies were noted in a substudy from the AFFIRM trial [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients in the rhythm control arm were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      (256 patients), amiodarone or a class I drug (222 patients), or sotalol and a class I drug (183 patients). The one-year endpoint was defined as the patient being alive, being in sinus rhythm at follow-up visits, still taking the drug (ie, no discontinuation for episodes of highly symptomatic AF), and needing no electrical or pharmacologic cardioversions. The likelihood of achieving the endpoint was significantly higher with amiodarone compared to sotalol (60 versus 38 percent) or a class I drug (62 versus 23 percent). In comparison to CTAF, amiodarone was not associated with a higher risk than sotalol of cessation of therapy for adverse effects (13 versus 16 percent).",
"     </li>",
"     <li>",
"      The SAFE-T trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , and placebo in patients with persistent AF for both conversion to sinus rhythm and maintenance of sinus rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/35\">",
"       35",
"      </a>",
"      ]. The rate of maintenance of sinus rhythm was significantly higher at one year with amiodarone than sotalol or placebo and with sotalol than placebo (52 versus 32 and 13 percent on intention to treat analysis and 65 versus 40 and 18 percent on treatment received analysis). The primary endpoint, the median time to recurrence beginning after day 28, was 487, 74, and 6 days in the three groups. However, among the approximately 25 percent of patients with ischemic heart disease, the median time to recurrence with amiodarone was not significantly different from sotalol (569 versus 428 days).",
"      <br/>",
"      <br/>",
"      There was no difference among the study groups in terms of adverse effects except for a small increase in minor bleeding among patients treated with amiodarone. The mortality rate was not significantly higher with amiodarone and sotalol combined compared to placebo (4.36 versus 2.84 per 100 person-years), but trials of patients with heart failure or myocardial infarction have not shown an increase in mortality with amiodarone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonrandomized studies of patients with chronic or paroxysmal AF refractory to most other antiarrhythmic agents have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    maintained sinus rhythm in 53 to 79 percent of cases during a 15 to 27 month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Amiodarone is less effective in patients who have AF for over one year or who have an enlarged LA. However, even in this group, the success rate with amiodarone may be as high as 50 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has also been evaluated as a prophylactic therapy to prevent AF after cardiac surgery. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    is not very effective in converting AF to sinus rhythm, but is useful in preventing recurrent episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. As an example, one study randomly assigned 253 patients with AF or atrial flutter to placebo or three doses of sotalol (80, 120, or 160 mg BID); the recurrence rate at one year was 72, 70, 60, and 55 percent, respectively, and the median times to recurrence were 27, 106, 119, and 175 days, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/48\">",
"     48",
"    </a>",
"    ]. As noted with other drugs, predictors of AF recurrence were the presence of coronary disease, duration of AF &gt;2 months before reversion, LA size &gt;60 mm, and older age.",
"   </p>",
"   <p>",
"    A number of studies have compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    to other antiarrhythmic drugs for preventing recurrent AF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, randomized controlled trials and a substudy analysis from AFFIRM demonstrated that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      was less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. After a mean follow-up of 16 months in CTAF, for example, amiodarone was associated with a significantly greater likelihood of being free from recurrent AF (65 versus 37 percent for sotalol and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ) and a longer median time to recurrence (&gt;468 versus 98 days) (",
"      <a class=\"graphic graphic_figure graphicRef69285 \" href=\"UTD.htm?4/48/4878\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/34\">",
"       34",
"      </a>",
"      ]. Similar findings were noted in SAFE-T [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Amiodarone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      appears to have equal efficacy to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/34,49,50\">",
"       34,49,50",
"      </a>",
"      ]. The best data come from CTAF, which randomly assigned 403 patients who had at least one episode of AF within six months of entry to low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , sotalol, or propafenone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/34\">",
"       34",
"      </a>",
"      ]. After a mean follow-up of 16 months, the proportion of patients free from recurrent AF was 37 percent with both sotalol and propafenone (",
"      <a class=\"graphic graphic_figure graphicRef69285 \" href=\"UTD.htm?4/48/4878\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Amiodarone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dofetilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    is a class III antiarrhythmic drug (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 2",
"    </a>",
"    ). The SAFIRE-D trial evaluated 204 patients with AF who were successfully cardioverted electrically or pharmacologically with dofetilide and maintained on a dose of 125, 250, or 500 &micro;g twice daily or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/51\">",
"     51",
"    </a>",
"    ]. The probability of remaining in sinus rhythm at one year was significantly greater for dofetilide compared to placebo (40, 37, and 58 versus 25 percent). The all-cause mortality was the same in the four groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701791#H8701791\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Dofetilide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results were similar in the EMERALD trial, which randomly assigned patients who were pharmacologically or electrically cardioverted to therapy with one of three doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    (125, 250, or 500 &micro;g twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (80 mg twice daily), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/52\">",
"     52",
"    </a>",
"    ]. After 12 months of therapy, AF recurred in 79 percent of placebo patients, 34 percent of those receiving the highest dose of dofetilide, and between 48 and 60 percent in the other groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is of concern that nonfatal torsades de pointes (TdP) or sudden death occurred in four patients in the high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    group [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/52\">",
"     52",
"    </a>",
"    ]. However, a pooled analysis of 1346 patients receiving dofetilide and 677 treated with placebo in randomized clinical trials of the treatment of supraventricular arrhythmias found that dofetilide was not associated with an increase in mortality (adjusted hazard ratio 1.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of an increase in mortality with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    is reassuring. However, because drug-induced TdP is relatively rare and can be treated if it occurs in a monitored setting, the impact of this complication may not be seen in analyses limited to overall survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dronedarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    is a derivative of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . In patients with AF, randomized trials with up to 12 months of follow-up have found that dronedarone prevents recurrent AF and was safe (including no increased risk of serious arrhythmias) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. However, in the ANDROMEDA trial in patients with advanced heart failure from LV systolic dysfunction, there was an increased risk of death with dronedarone and the trial was stopped early [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/57\">",
"     57",
"    </a>",
"    ]. As a result, dronedarone is contraindicated in this population of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H9#H9\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Antiarrhythmic drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the ATHENA trial 4628 patients with AF were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients with NYHA class II or III heart failure comprised 21 percent of the study population, but patients with NYHA class IV heart failure were excluded. After a mean follow-up period of 21 months, dronedarone significantly reduced the primary outcome of death or cardiovascular hospitalization (31.9 versus 39.4 percent, hazard ratio 0.76, 95% CI 0.69-0.84) and the secondary outcome of cardiovascular death (2.7 versus 3.9 percent, hazard ratio 0.71, 95% CI 0.51-0.98). Dronedarone is the only antiarrhythmic drug that has shown a salutary effect on mortality. Maintenance of sinus rhythm was not one of the endpoints in ATHENA.",
"   </p>",
"   <p>",
"    <br/>",
"    The DIONYSOS study was a short-term (median duration of seven months) comparison between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    to assess the differences in drug tolerability and AF recurrence in 504 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/59\">",
"     59",
"    </a>",
"    ]. Sixty percent of the patients had persistent AF. The authors found that the composite primary endpoint of AF recurrence or premature study drug discontinuation occurred in 75.5 percent of patients taking dronedarone, but only 58.8 percent of patients taking amiodarone. This endpoint was primarily driven by AF recurrence on dronedarone compared to amiodarone (63.5 versus 42.0 percent, respectively). Drug discontinuation and the main safety endpoints of extra-cardiac toxicity only tended to be less with dronedarone, but did not reach statistical significance. It is possibly that with longer follow-up periods there would have been a greater difference in noncardiac side effects, since the toxicity with amiodarone is typically manifest after several months to years of use.",
"   </p>",
"   <p>",
"    In a meta-analysis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    trials prior to the DIONYSOS study, where the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    versus dronedarone was estimated with the use of indirect comparison and normal logistic meta-analysis models, a similar conclusion was reached [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/60\">",
"     60",
"    </a>",
"    ]. Amiodarone was found to be more effective in maintaining sinus rhythm, but at the expense of greater drug discontinuation secondary to adverse events.",
"   </p>",
"   <p>",
"    The PALLAS trial, which was stopped early due to an increase in adverse events in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    , evaluated the potential use of dronedarone to improve cardiovascular outcomes in patients with permanent AF. This trial is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H58992353#H58992353\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Concerns about dronedarone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ibutilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is only available for intravenous use and therefore is useful for the acute reversion of AF, not for long-term prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13502785\">",
"    <span class=\"h2\">",
"     Vernakalant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vernakalant is considered a relatively &ldquo;atrially-selective&rdquo; antiarrhythmic agent since one of its main actions is to inhibit the ultrarapid potassium current (IKur) and the acetylcholine potassium current (IKAch), both of which are predominantly found in the atria. Vernakalant also mildly inhibits other potassium channels and, to a much lesser extent, the sodium current. It has been studied for acute cardioversion of AF using an intravenous formulation only; trials of this drug for the maintenance of sinus rhythm are in progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     BETA BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to support the use of beta blockers (aside for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ), in the absence of other antiarrhythmic drugs, for the prevention of AF. In patients with heart failure (HF) due to systolic dysfunction, chronic treatment with certain beta blockers reduces mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence that beta blockers may also reduce the likelihood of the development of AF in patients with HF. A systematic review including seven randomized trials of 11,952 patients evaluated the efficacy of beta blockers for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/62\">",
"     62",
"    </a>",
"    ]. Among patients who were in sinus rhythm at baseline and were followed for six months to two years, the incidence of new onset AF was significantly lower in patients treated with beta blockers than those assigned to placebo (28 versus 39 per 1000 patient years). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is whether beta blockers, which are felt to have some antiarrhythmic properties (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 2",
"    </a>",
"    ), are effective for preventing recurrent atrial fibrillation in patients with no heart disease. The evidence to support their use for this purpose is scant, and any reduction in the reported frequency of AF may be attributable to improved rate control that may render recurrent AF silent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     VERAPAMIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium channel blocking agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    impair conduction and prolong refractoriness in the AV node. They have been used both acutely and chronically to slow the ventricular response in AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H13#H13\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Calcium channel blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    has also been investigated for its effectiveness in maintaining sinus rhythm after cardioversion. The rationale for this approach is the observation that the electrical remodeling that occurs during AF is thought to be due, at least in part, to abnormal calcium loading during rapid atrial rates. In studies in animals and humans, verapamil has been shown to prevent electrical remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=see_link&amp;anchor=H186295411#H186295411\">",
"     \"Mechanisms of atrial fibrillation\", section on 'Electrical remodeling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    as a single agent was not effective in preventing AF recurrence in the VERDICT trial, in which 97 patients with persistent AF were randomly assigned to either verapamil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/66\">",
"     66",
"    </a>",
"    ]. There was no difference in AF recurrence rates at one month. It was suggested that verapamil may be effective only when given with a sodium or potassium channel blocking agent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Verapamil with another agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the observations cited above, several studies evaluated the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    with another agent in preventing recurrences of AF. In the small VEPARAF trial, the addition of verapamil to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    significantly reduced the incidence of recurrent AF within three months of cardioversion compared with either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/68\">",
"     68",
"    </a>",
"    ]. The larger PAFAC and SOPAT trials found the combination of verapamil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    to be comparable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and superior to placebo, in preventing AF recurrence.",
"   </p>",
"   <p>",
"    In PAFAC, 848 patients with persistent AF were cardioverted and then randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/69\">",
"     69",
"    </a>",
"    ]. Patients used an event recorder to record and transmit at least one ECG daily during a mean of nine months of follow-up. The incidence of death or any AF recurrence was significantly lower for both sotalol and for quinidine plus verapamil than for placebo (67 and 65 versus 83 percent). Serious adverse events were not more common with quinidine plus verapamil than with sotalol, and the only episodes of torsades de pointes occurred with sotalol.",
"   </p>",
"   <p>",
"    In the SOPAT trial, 1033 patients with recurrent symptomatic paroxysmal AF were randomly assigned to placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or one of two dose combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/70\">",
"     70",
"    </a>",
"    ]. As in the PAFAC trial, patients recorded and transmitted at least one ECG daily with an event recorder. The mean time to first AF recurrence was prolonged significantly in all three active treatment groups compared to placebo. At a mean of eight months of follow-up, the number of days of symptomatic AF was reduced significantly for all three active treatment arms compared to placebo. There was no difference between the sotalol and the two quinidine plus verapamil treatment groups in either of these efficacy endpoints or in the incidence of serious adverse side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to conventional antiarrhythmic drugs, a number of other agents have been investigated for the purpose of suppressing AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     ACE inhibitors, angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) reduce the incidence of atrial fibrillation in selected patient populations. In a recent meta-analysis of 26 randomized trials that evaluated the effect of ACE inhibitors and ARBs on the prevention of AF, it was demonstrated that both classes of drugs had a similar beneficial effect on AF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/71\">",
"     71",
"    </a>",
"    ]. The effect was more potent for recurrent AF compared to primary prevention of AF (OR 0.45 versus 0.80, respectively). ACE inhibitor or ARB effect on AF was additive to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    when used concurrently and endured even in patients with depressive LV function. This issue is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=see_link\">",
"     \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a primary antiarrhythmic agent, magnesium affects atrial electrophysiologic properties. Some studies, particularly those in patients undergoing coronary artery bypass surgery, have found that magnesium deficiency is associated with AF and that magnesium supplementation reduces its incidence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=see_link\">",
"     \"Significance of hypomagnesemia in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link&amp;anchor=H97330379#H97330379\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Ineffective or possibly effective therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of oral magnesium therapy in the prevention of recurrent AF after cardioversion was evaluated in one study of 301 patients who were followed for at least six months after the restoration of sinus rhythm; magnesium therapy alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    was",
"    <strong>",
"     ineffective",
"    </strong>",
"    for preventing recurrent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that statins may prevent recurrences in patients with lone AF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/74,75\">",
"     74,75",
"    </a>",
"    ] and after cardiac bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/74,76\">",
"     74,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Aldosterone Blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;These drugs have been useful in the treatment of heart failure.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    have effects on atrial electrophysiologic properties in experimental animals, but no studies in patients with AF have been done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189490085\">",
"    <span class=\"h2\">",
"     Fish oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that fish oil consumption is associated with a lower risk of the development of recurrent AF. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H20#H20\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DRUG-REFRACTORY AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are refractory to individual antiarrhythmic agents plus an AV nodal blocker or develop side effects on doses necessary for arrhythmia prevention. There are limited data to support the use of combination antiarrhythmic drug therapy, and this approach may expose the patient to a greater risk of proarrhythmia and other side effects. As a result, combination therapy is not recommended.",
"   </p>",
"   <p>",
"    Such patients can be treated with a rate control strategy or referred for nonpharmacologic therapy of AF. These options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiofrequency catheter ablation (RFA), which is the most common of these approaches. The 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA/ESC",
"      </span>",
"      guidelines recommend RFA as a second-line intervention in many patients who are refractory to antiarrhythmic drugs (",
"      <a class=\"graphic graphic_algorithm graphicRef83173 \" href=\"UTD.htm?35/57/36766\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical procedures such as the maze operation, particularly for patients undergoing cardiac surgery for another indication. Some centers also offer &ldquo;mini-maze&rdquo; operations using limited bilateral thoracotomies as standalone procedures as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"       \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     HYBRID THERAPY IN PATIENTS WHO DEVELOP ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter can occur after the initiation of antiarrhythmic drug therapy in patients with AF, especially with the use of class IC agents or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . While the mechanism for this is not clear, it may be due to conduction slowing and blockade of most, but not all, of the reentrant pathways. The wave front of activation would therefore be forced to follow one unique pathway that is least altered by the drug.",
"   </p>",
"   <p>",
"    In such patients, radiofrequency ablation is an effective approach for treating atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/24/12682/abstract/30,31,78,79\">",
"     30,31,78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use drug therapy to maintain sinus rhythm in patients with atrial fibrillation (AF) are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the important points made in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main goal of drug therapy to maintain sinus rhythm is to reduce symptoms by decreasing the frequency and duration of episodes.",
"     </li>",
"     <li>",
"      The primary endpoint of many clinical trials involving antiarrhythmic drugs has been time to first recurrence of AF. However, there is great variation in efficacy of antiarrhythmic drugs from patient to patient. Although a drug may be shown to significantly prolong the time to recurrence of AF in a clinical trial, some patients will experience no benefit and others will experience a dramatic reduction in AF frequency.",
"     </li>",
"     <li>",
"      Other outcomes are also important. These include the effect of the drug on overall AF burden, AF episode duration, symptoms, ventricular rate control, and hospitalizations. A single recurrence of AF on a drug does not necessarily indicate treatment failure or require a change in therapy.",
"     </li>",
"     <li>",
"      When the rhythm control strategy is chosen, the recommended drugs for maintenance of sinus rhythm vary with the clinical setting (",
"      <a class=\"graphic graphic_table graphicRef78424 \" href=\"UTD.htm?25/39/26236\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef83173 \" href=\"UTD.htm?35/57/36766\">",
"       algorithm 1",
"      </a>",
"      ). Optimal antiarrhythmic drug therapy should be both effective and have a low incidence of toxicity, including proarrhythmia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      are effective in the maintenance of sinus rhythm. Of these, amiodarone is the most effective, but is associated with the development of more frequent side effects. Dronedarone is also associated with the development of significant side effects as well as worse outcomes in some groups of patients with AF. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Amiodarone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Dronedarone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/1\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/2\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/3\">",
"      Falk RH. Atrial fibrillation. N Engl J Med 2001; 344:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/4\">",
"      Connolly SJ. Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. Am Heart J 2000; 139:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/5\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/6\">",
"      McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/7\">",
"      Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/8\">",
"      Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/9\">",
"      Lafuente-Lafuente C, Mouly S, Long&aacute;s-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/10\">",
"      S&ouml;dermark T, Jonsson B, Olsson A, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J 1975; 37:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/11\">",
"      Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J 1984; 65:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/12\">",
"      Reimold SC, Chalmers TC, Berlin JA, Antman EM. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. Am Heart J 1992; 124:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/13\">",
"      Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/14\">",
"      Karlson BW, Torstensson I, Abj&ouml;rn C, et al. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/15\">",
"      Szekely P, Sideris DA, Batson GA. Maintenance of sinus rhythm after atrial defibrillation. Br Heart J 1970; 32:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/16\">",
"      Madrid AH, Moro C, Mar&iacute;n-Huerta E, et al. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993; 14:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/17\">",
"      Hjelms E. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment. Scand J Thorac Cardiovasc Surg 1992; 26:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/18\">",
"      Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/19\">",
"      Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989; 80:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/20\">",
"      Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991; 114:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/21\">",
"      A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation 1995; 92:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/22\">",
"      Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997; 79:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/23\">",
"      Antman EM, Beamer AD, Cantillon C, et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/24\">",
"      Geller JC, Geller M, Carlson MD, Waldo AL. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Am J Cardiol 2001; 87:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/25\">",
"      Meinertz T, Lip GY, Lombardi F, et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002; 90:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/26\">",
"      Pritchett EL, Page RL, Carlson M, et al. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003; 92:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/27\">",
"      Chimienti M, Cullen MT Jr, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 1996; 77:60A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/28\">",
"      Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 1996; 77:66A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/29\">",
"      Zarembski DG, Nolan PE Jr, Slack MK, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/30\">",
"      Schumacher B, Jung W, Lewalter T, et al. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol 1999; 83:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/31\">",
"      Nabar A, Rodriguez LM, Timmermans C, et al. Radiofrequency ablation of \"class IC atrial flutter\" in patients with resistant atrial fibrillation. Am J Cardiol 1999; 83:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/32\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/33\">",
"      Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996; 78:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/34\">",
"      Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/35\">",
"      Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/36\">",
"      Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000; 84:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/37\">",
"      AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/38\">",
"      Dorian P, Mangat I. Restoring sinus rhythm in atrial fibrillation: a Pyrrhic victory? J Am Coll Cardiol 2003; 42:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/39\">",
"      Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/40\">",
"      Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/41\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/42\">",
"      Brodsky MA, Allen BJ, Walker CJ 3rd, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/43\">",
"      Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/44\">",
"      Horowitz LN, Spielman SR, Greenspan AM, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/45\">",
"      Skoularigis J, R&ouml;thlisberger C, Skudicky D, et al. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol 1993; 72:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/46\">",
"      Gallik DM, Kim SG, Ferrick KJ, et al. Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. Am Heart J 1997; 134:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/47\">",
"      Alt E, Ammer R, Lehmann G, et al. Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. Am Heart J 1997; 134:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/48\">",
"      Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1999; 84:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/49\">",
"      Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/50\">",
"      Bellandi F, Simonetti I, Leoncini M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001; 88:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/51\">",
"      Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/52\">",
"      Ferguson JJ. Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association. Circulation 1999; 99:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/53\">",
"      Pritchett EL, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am Heart J 1999; 138:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/54\">",
"      Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003; 24:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/55\">",
"      Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 2005; 23:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/56\">",
"      Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/57\">",
"      K&oslash;ber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/58\">",
"      Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/59\">",
"      Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/60\">",
"      Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/61\">",
"      Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/62\">",
"      Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007; 28:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/63\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/64\">",
"      Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/65\">",
"      Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/66\">",
"      Van Noord T, Van Gelder IC, Tieleman RG, et al. VERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2001; 12:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/67\">",
"      Knight BP. Calcium channel blockade for prevention of recurrent atrial fibrillation: have we reached a VERDICT? J Cardiovasc Electrophysiol 2001; 12:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/68\">",
"      De Simone A, De Pasquale M, De Matteis C, et al. VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J 2003; 24:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/69\">",
"      Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/70\">",
"      Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J 2004; 25:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/71\">",
"      Zhang Y, Zhang P, Mu Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/72\">",
"      Frick M, Darp&ouml; B, Ostergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J 2000; 21:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/73\">",
"      Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/74\">",
"      Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008; 51:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/75\">",
"      Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/76\">",
"      Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128.",
"     </a>",
"    </li>",
"    <li>",
"     Coumel P, LeClerq JF, Attuel P. Paroxysmal atrial fibrillation. In: Atrial fibrillation, Kulbertus HE, Olsson SB, Schlepper AB (Eds), Hassle, Molndal 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/78\">",
"      Huang DT, Monahan KM, Zimetbaum P, et al. Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/24/12682/abstract/79\">",
"      Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J 2000; 21:565.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1038 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12682=[""].join("\n");
var outline_f12_24_12682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYSTEMATIC REVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASS IA ANTIARRHYTHMIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLASS IC ANTIARRHYTHMIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLASS III ANTIARRHYTHMIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sotalol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dofetilide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dronedarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ibutilide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13502785\">",
"      Vernakalant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      BETA BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      VERAPAMIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Verapamil with another agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ACE inhibitors, angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Aldosterone Blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189490085\">",
"      Fish oil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DRUG-REFRACTORY AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      HYBRID THERAPY IN PATIENTS WHO DEVELOP ATRIAL FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1038|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/57/36766\" title=\"algorithm 1\">",
"      Algorithm for the maintenance of sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1038|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/25/19870\" title=\"figure 1\">",
"      Rhythm versus rate control AF AFFIRM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/51/9022\" title=\"figure 2\">",
"      Rhythm versus rate control AF RACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/4/19534\" title=\"figure 3\">",
"      Proarrhythmia with class Ic antiarrhythmic drugs in CAST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/48/4878\" title=\"figure 4\">",
"      Recurrent AF after amiodarone propafenone and sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1038|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/39/26236\" title=\"table 1\">",
"      ACC AHA ESC drugs maintain NSR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 2\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=related_link\">",
"      Significance of hypomagnesemia in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_24_12683="Need for anesthesia consult";
var content_f12_24_12683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for consideration of a preoperative anesthesia consultation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Massive obesity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asthma requiring medication",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe hypertensive disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maternal coagulopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       History of anesthetic complications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe facial or neck edema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Extremely short stature",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Short neck, decreased mobility of the neck",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Difficulty opening the mouth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Protuberant teeth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anatomic abnormalities of the face, mouth, neck, or jaw",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serious medical or obstetrical conditions",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in American College of Obstetricians and Gynecologists. ACOG Committee Opinion 104, Washington DC 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12683=[""].join("\n");
var outline_f12_24_12683=null;
var title_f12_24_12684="Clinical history in returning travelers";
var content_f12_24_12684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key elements of the history in returning travelers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Geography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Countries visited or passed through; urban or rural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dates of travel and duration of stay in each place",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Means of transportation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accommodations (eg, hotel, dormitory, local household, tent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activities and exposures during travel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex or other intimate contact (eg, type, number of partners, barrier protection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animals, including birds (eg, shared living quarters or physical proximity, seeing rodents, bites, licks) or animal products (eg, hunting, skinning, other)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthropod (eg, seeing or receiving bites from mosquitoes, flies, ticks, fleas, other)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Needle and blood exposure (eg, shared needles, injections, acupuncture, tattoos, ear or other body piercing, dental work, transfusions, surgery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food and beverages (eg, raw or undercooked flesh, unpasteurized milk, tap or surface water, local delicacies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soil and water contact (eg, recreational, such as hiking, boating, swimming, hunting, spelunking or professional activities, such as archeological digs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Host factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age and sex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical problems and past surgery (eg, splenectomy, gastrectomy, HIV infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Past infections and vaccines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications, including immunosuppressive and immunomodulating agents, over the counter drugs, antipyretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Past medical history, including immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preparation for travel (eg, vaccines, chemoprophylaxis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12684=[""].join("\n");
var outline_f12_24_12684=null;
var title_f12_24_12685="Interpretation 72 hour fast";
var content_f12_24_12685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypoglycemia: Interpretation of 72-hour fast",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptoms, signs, or both",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glucose (mg/dL)/(mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Insulin (&micro;U/mL)/(pmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        C-peptide (nmol/L)/(ng/mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proinsulin (pmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &beta;-Hydroxybutyrate (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glucose increase after glucagon (mg/dL)/(mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Circulating oral hypoglycemic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibody to insulin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &lt;55/3",
"       </td>",
"       <td>",
"        &lt;3/20.8",
"       </td>",
"       <td>",
"        &lt;0.2/0.6",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        &gt;2.7",
"       </td>",
"       <td>",
"        &lt;25/1.4",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &lt;55",
"       </td>",
"       <td>",
"        &gt;&gt;3",
"       </td>",
"       <td>",
"        &lt;0.2",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        &le;2.7",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Neg (Pos)",
"       </td>",
"       <td>",
"        Exogenous insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &lt;55",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"       <td>",
"        &ge;0.2",
"       </td>",
"       <td>",
"        &ge;5",
"       </td>",
"       <td>",
"        &le;2.7",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Neg",
"       </td>",
"       <td>",
"        Insulinoma, NIPHS, PGBH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &lt;55",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"       <td>",
"        &ge;0.2",
"       </td>",
"       <td>",
"        &ge;5",
"       </td>",
"       <td>",
"        &le;2.7",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Neg",
"       </td>",
"       <td>",
"        Oral hypoglycemic agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &lt;55",
"       </td>",
"       <td>",
"        &gt;&gt;3",
"       </td>",
"       <td>",
"        &gt;&gt;0.2*",
"       </td>",
"       <td>",
"        &gt;&gt;5*",
"       </td>",
"       <td>",
"        &le;2.7",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Pos",
"       </td>",
"       <td>",
"        Insulin autoimmune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &lt;55",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        &lt;0.2",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        &le;2.7",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Neg",
"       </td>",
"       <td>",
"        IGF&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &lt;55",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        &lt;0.2",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        &gt;2.7",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Neg",
"       </td>",
"       <td>",
"        Not insulin (or IGF)-mediated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patterns of findings during fasting or after a mixed meal in normal individuals with no symptoms or signs despite relatively low plasma glucose concentrations (ie, Whipple's triad not documented) and in individuals with hyperinsulinemic (or IGF-mediated) hypoglycemia or hypoglycemia caused by other mechanisms.",
"    <div class=\"footnotes\">",
"     Neg: negative; Pos: positive; PGBH: post gastric bypass hypoglycemia; NIPHS: noninsulinoma pancreatogenous hypoglycemia syndrome; IGF: insulin-like growth factor.",
"     <br>",
"      * Free C-peptide and proinsulin concentrations are low.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Increased pro-IGF-II, free IGF-II, IGF-II/IGF-I ratio.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication to include mmol/L equivalent data. Reproduced with permission from: Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:709. Copyright &copy; 2009 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12685=[""].join("\n");
var outline_f12_24_12685=null;
var title_f12_24_12686="Contents: Tumors immunocompromised host";
var content_f12_24_12686=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Tumors immunocompromised host",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Tumors immunocompromised host",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12103\">",
"           AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/37/18009\">",
"           AIDS-related Kaposi sarcoma: Staging and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/4/7242\">",
"           AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20042\">",
"           AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7321\">",
"           AIDS-related lymphomas: Primary central nervous system lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30969\">",
"           AIDS-related lymphomas: Primary effusion lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38346\">",
"           AIDS-related lymphomas: Treatment of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/33/1562\">",
"           Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27206\">",
"           HIV infection and malignancy: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/31/30202\">",
"           HIV infection and malignancy: Management considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/14/18665\">",
"           Preinvasive and invasive cervical neoplasia in HIV-infected women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/7/21623\">",
"           Pulmonary involvement in AIDS-related Kaposi sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9750\">",
"           Pulmonary manifestations of HIV-associated lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/19/42294\">",
"           Systemic therapy for malignancy in patients on anti retroviral medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26455\">",
"           Virology of human papillomavirus infections and the link to cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Organ transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12505\">",
"           Clinical manifestations and diagnosis of acute renal allograft rejection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34170\">",
"           Development of malignancy following solid organ transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/63/31738\">",
"           Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/26/40362\">",
"           Long-term management of adult liver transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/39/28280\">",
"           Malignancy after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/60/12233\">",
"           Noninfectious complications following lung transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23338\">",
"           Treatment and prevention of post-transplant lymphoproliferative disorders",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-4C8BBCFE39-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f12_24_12686=[""].join("\n");
var outline_f12_24_12686=null;
var title_f12_24_12687="Melanoma pleural metastases";
var content_f12_24_12687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic metastases from melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 239px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADvAU8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiijFABRRR16UAFFGKACTgDNABRV+00e/ukDw27FD0YkAfrWrY+C9Xvc+SkXHq/8A9agDm6K7Z/h1qkKFrhgoH91c/wBRVGfwvHbgia4mDAdoh/8AFUAcvRW82hQD/l6lHfmEf/FUn9hQd75h6Zh/+vQBhUVsnQ8qGivYCpOMurj+QNRrokzkCO4tnJ9Cw/mooAyqK2D4a1QpvitxKnrG4P6dayXRkYq6lWHYjBoAbRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRUttby3UojgjaRz2FbVj4eEjf6bcrGf+ecQ3t/gKAMCpre1uLkkW8MkpHUIpb+Vdva6Vp8GFXTy2OTLOdxP4dP0qaZbmRBBaMVUdI40wo/AUAcna+HdRnYZiWEf3pW2j/GtJPCcagm41KEEDO2Jdx/UiursvDWp3ERSGJ5mfGd/AB9q6PR/hjqU6/6RIsOcE85OKAPNYfD+nCdVMtxOv+yQuf0NddofgyMIr/ZokGc5lXecfjXp+kfD2x0wrJIQ0gHJPJrWvbG0hjAQZIHvQBxFt4Ptpx5e4Rqe6RgVpJ8LtKCbvtku9hyCR1/Kte3dY5h0A/lW5azQuPmfHHWgDzXWPAcNhGXhWSZccbsf4U7QPA1newl5lCsDyu1Tj26V6DqktqLR0NyGOOe9cXo+vx6drhilkJt5SefSgB958N7D7O8kMuxgCcBFrlfCvh+2v9ZWKW4kEKZ3ZAFe0pJbzQ5gbejLwB71w/g7RLO58aHTrm9+y+cRyO3Hr0oA6CbQLGDTnVI0iG3h1AyfxqTw5p0VparsBfPc96xvikl74a1Iadb6mLm3ChgQozj0NUNE+ItlaWawTIWmUYzjvQB2+pwl4X3qF4wOMV5/qUyRXRjuIo2jzjcVzmreqeNftqMsEdwFI/gj/wAa5i+1a5mVhFp0shB+9KwGfyoA6XSfDul6w4IjgVW6kKMVqXPw30aVCuVQjoyoOa83g1TXbRz9msRFznhs1YbxJ4xdgsahT2GOlAHWn4SWH3oL6dfbAxVS8+E7smBcLMMcZjwR+IrETxB43hG5pYR2ywGK6LS/GOvJCReNbT+uzg0Acnf+ArnTHOY7gIOjR/MKo3ekrNIES43Oo+aOZcgn3Br0OP4lWEd0LfWEksxnG+RCV/MVoav4i+G/iiRVjvraG5jjEYuVJjdyPY4BoA8L1Hwqk9wSsLwZ/jhGU/L/AOvXK6hpFxaSSbP38SdXQdPqO1e9ah4Ru7NvPt5RLB1BB6j3FcxrPh+WdjPag292PvDtIPSgDxs0V095o8d7v+zRrbXqcGDokn09D+n0rm54ZIJnimQpIhwynqDQAyiiigAooooAKKKKACiiigAooooAKKKltbeS6mWKFdzt2oAiAJ4Aya3bDw/K0UVxdEJExz5Y5Yj39Kv6NpvlOotk8y4PDyHonsv+Ndzo2hkxj7TxEOT6tQBmaTo6zRlLOFY4if4ATn8eprobXwwQP3bLEf8AZU5rpLSFEAWJAqAcADtXWeF/Dv8AacglvJRa2APzyn7zeyjuaAOB0TwdqOqajHb24aZXbBBUnHuT2Fehy/DT+wZ40vJrViy7ikSnC+xPU12ug/aRI9hoNntsUbmUjDP7s39Kf441rSoLf/SbhZNaUKrpFlkH1Prj3oA5q0s7S3H7qFYwvcjrVa61K2s2LzXGQOigiuW1jWZ5Q2WCLz09K4HVNfPnMlvsds4JagD1CbxKl1MyxbiByP8A61UZL1pzg7gB615tZeJ5bWTdcxKUP8Qro7XxRp864ViH9CDQB0cfPJOR+VEkgRSWJAAJ61kpqyz4FqpZvU8Yp8kDXSD7Y5x/dXgUAc7f3Tu0riZyCcbI2yf0rImFrKD9qgkU+pzn+ld5BbQ2+BDGqr3AFLcLE8bB409OR0oA5jw949utDsprTT4HdiNgckA49OhrNt9avDqDaleli/QIpwenrRqKob8i2TazZXIHFb+j+HobcK8gLv15oAoSXOr6yVMYECMMlpBvJ/EitGx0GRSGnmDN7LiugYKoUAAZ4xSO208EnHXjFAEUNpFEmFA+9UvkwkjcgHocUpbOCVHXtSHkHIwPWgBCiZOE+UnpQIo8ttTHvingYGEGM8GpFXaOxHr3oAj+yxOPnjVvrSrbQod2xMdQMCiST5eCSPT3qCSQjAGeRQBU1qxsdRha3ktoi5GN5UcfQivBPFehTeH9Xks5jvXAaOTaQGU19DQEKwZzhR0Fcz8UNN/tjw67RoDPbESIQOfcflnigDyzwx401nQLmEwXk8tojAvayPlHHpznH4V6pofjTTPFW6MwmzvAM+WzDBPfaeM14NQCVYEHBHQjtQB7n4j0KG5beoSKYcbgOoFef6tp5uJGt75dtwAAl2RwB6H1FX/DXi030aWGrziKYYWC5bof9l/8a2tXhdYng1BBHIRwwOA3vmgDym9tpLS5kgmXDocH0PuPb3qGu5vbWO/sls7h8PGCbeU8cn+En0NcXdW8trcPDOhSRDgqe1AEVFFFABRRRQAUUUUAFFFKil2CqCWJwAO9AD7aCS5mWKBC8jdAK6/QtLBu4dPibmQjzZBwT7fSo9DtP7OEh2CS4CbpCP4R/dH9a6PRn06HF5JIwfP+qXG45oA6iLRre1mVIEAQY+Y961VUECNBkkcj0qveXiRWBugpGFG0D9K6r4Y6KNbvopbo7YIMTT5GcqOdv49KANLQPDckNjHqmqQuun8+XGx5mfsPp159q7nS9FnjjXVvE862mnoAYoVPY9AAOnb3rttbGmLpUOoaiBHaWv7wIcAd8CvmL4ifGaLXvExsbKJzZwuUiAYbR2ycHk0Aek+NPHJvbcaf4fVrWyXIYodrOPfFefyM8mS5IPrmo9KYXMCysCoPIFT3hjt4i0jDjr6frQBj62JHs3REyzAiuCNs4kfpgHpjpW1q3jnTIrsxF3bB2kpggU+wvbLUXBgljlDdOQSPrQBzN1byklVO8ZzjOKm0zRpDcI25mbPQGu1TQkkbdkYPb+tW4dI+z4Ixn1AoAsadbrawRqqjjkk96vODtGRnHOaYi7ABjp0zSrkqTtP40AC/OM5Jx6io5m8tGOMkdjVu2dMgY69s1neJNQjjRbaADz+rEUARX1tA1xA0aBXkILkcZrUb5WA/TNY2m5ubuHzcnZjr0+lbl0wExCqM44xQA2RsleOeRTD83HYdQKRgxAJGc07GFxwfSgCMfKeGJP6VNHhjj/69RH26+mKsIMjBAA6Y9aAHKBkYx7Ux2+YjGDRIxAA4yfTtUB4PP4+9ACEknIAI7elRtnkt96hz8uMke5pOSeTzQA/OFXByfWiWNXjcSL8rDBpoO08E/hSTOBGzYxgH71AHzbfR+TeTx/3HYfrUNX9fx/bN5gAfvDVCgAr0bwP4lgvbddF1wh8/LBM3X2Un+tec0AkdDigD0/xD4dnslaaLMltnIH92sK/tF1ez2BAt9Cn7p/8Anqv9w+47H8K6H4deKTqN5aaRqKmSSQrEGc535OOnrXUePvA0+hTrdW6Nsf5gAhG2gDwRlKsVYYIOCKK6nxVYCaJtTjAWTIWdAuOf7/Hr39/rXLUAFFFFABRRRQAV0/hfTdrLdSrmUqWiUnoP7xrK0awNzKZ5APs0Jy+TjPoB65rprK5P2tZyAiumwAH5VHoKAOs8BaGxW5nvE/1q7SAeopLzwpHpupRzoT9m64J5+n0qfwvqlza3BjuSptduFbHApuvapPeXrrErbIVBUA9SfWgB97cfbXitINzAn5vTAxXvPw/ax8MeGjdXTklwHOeQSBwK8Q0C1Wyhjkuv9Y53tu5I9q6DUNUlvFFv5jCFVAVQcAe+KAOj8a+LL/xlby2txIFsG4WOMYzjvn868Q1Lw9p2g6wkk1w8YckohOSas+IPiCdPuXstKhjmWPAM7HgnvgVweua5c63ercXzkFegTt9KAPbNK1KMwxgOuxF/SvNviL4ouL++lsYXUWq4zjqT9awU8R3UNssNuNoH3mZixaseeVppWd8bicmgBlWdNvJLC+huYW2vGwP19qrUUAfS+k3MV3p1tcp0mjVwMeoq43OSx468+lYfgpi3hLTGA5EQXmtpWODxn6UADAYxkkd8cVGxVcq/zAdO1SSH92c8f3cGqRmVnZWPzD+dAEl5fWdpZNKpO9RkDtmuTtXl1GZmONzMSSBwKu6wUW4WJl+RhndnGKrW8n2aYA/6s0AdFZ26wmPjJz3Na0mFbIBVfQc1kxTI8KPG+QpHNa28zQ5JoAiYjBGSSPemhQBwRyBnFDkxtyp2nvjin5Vl+XBHrigASPDc5x9KeB2x79KRCA3GCB1NI7DB5/GgBspCjBwB9KhYbucZHY4p+MsOPqTSt8ozzzwBQBXC4HvnkCkIyCCfqKcwAGCSec5ppB5yTz68UAAJ6AD8ap6zKyWMuw4Y/LWgWwAMcj2rmPGepCzs5TuyI1LEDuewoA8V1aUz6ncyH+Jz/hVShiWYk9Sc0UAFFFFAF3RL5tL1iyv4wC9tMsoB74Oa/Qq6t9P+I3w+s9Qtdri6thPCUPRiv3fzyPwr86K+rf2MvGkksepeELyYssS/bLIMegziRR+JVse7GgDznxnoMmi6hcefDuiZjG8bjvnpXk2sWD6fdlCP3TjfE2c7kycfjX2V+0B4ZWSQ3SoBHdgZIX7si4z+Yr5V1W1W8tJoycXFvloxt+9j7y/pn8KAORooooAKms7aS7nWKEZY9SegHqfao40aR1RASzHAA7mux06wjtbY27ACdxmSRec+i/QUARTpDFarBZ48uNctjqzdyffinWkiwW0TyqJASQVJ5qMRC08xJAXlfhAO9WYYzOY7dI8zsMYB6UAaI1KIbSqfvMYCKa7TQ9L22YknBMp+Ysw5rG8OeHxA6y3G15QMADoteseB9Bl165kigiJjgXJOOme1AHENG0kjEKCoAAz9aoeIJ1sNJvrpnCskbbBnHzY4H51v+JbJ9C166tLjgo3CkYwTXmvxYum+y6dbqT5bs7n0OMf40AebnrRRRQAUUUUAFKgywHqcUlFAH0T4SxH4cs4wjJsjAKleSfWtY8g8Yryj4feMYLSzNhq1w0aoP3chHGPTNd7b+I9JumVIdRtpHbgKJBk0Aa0rD5mzx/KuVub4Qag02c5OME9a6WZQ8bKHA3dSK47WdLk+0mRPnj689v8APNAFnUDJdWrXBdY/L5wa0vsDXFlHJHtLkZ6Vz8EkM0D24SRpHbrjPSu6tHH2aNUJ+VeQeooA5cx3EQ2ESROPuuvT6Gr+j+IWR1t9Qj2MCfmHQ/hW3cx+Yq7uWNZt9p1vc8suJezUAbX2m3kj/dsrKR0HNZ08jxzDZ9w8jiuauJJtOfCk/XtWjo+qi4Rxcx4UDGT0NAHSRhvKDZOPrSk+vU+lU9OmO0xyEhhz9RVsk7RtVh24oABwGwoBz6Ux8sx3ZwKdwSN2CoHbqacFAX0z2PpQBWYnJwc4GBmkAJIY8fTmllwDyoJFAdVXLdu/pQA2RgA2ByP4q8a+I2tG7v5LOJ96IRvYHOSO1dz4v8YW2kWM8dqxkvZAUTHRc968SJLEk9aACiiigAooooAK3PA/iK68KeLNL1qxleOS0nV22nG9M/Mh9QVyD9aw6KAP0J8d6pYeJ/hna6xpcyT2k7RTxODnAORg46EZwR2IxXx34hg+xaxOyDB3GQfga2/hR4turbwhe6LLIxtFmDonoScn9au+NbHfaJexxgoBvbigDybxDaiC+82KMJb3A8yMAcD1H4HNZddXqUJu9InjA3Pbfv0Of4ejY/Q/hXKUAb2jWZt4FvHAMjj90PQdM/Wt60T/AEbzn4FAVrhXDLtj4wAdo47VM0bvYQxRgAgngfzoAi0+WQ6tHJDGJHyOG6Gu5sdPUzfa5oYlnbsg6e1Z/h/SlsrUMxzI53A/UV0lhiV8cjB/WgC3ZWiiPJPPbmvdvgdYi38M3FwygPPcNzj+EAD+ea8WI8uPGST3AFe7/B4EeB7bnGJZP/QqAPI/jRYiT4hXsjj92UjP47BXjHxJ0xr3TUlhX57XLEY6r3r2v4mXyah4tv5UcFVfYMdCFAXP6VxbxCRAHGQRj60AfOVFe16z4K0zUY3ZYvKuCOHQ4/TpXl3iLw9daLMRKjtDnAkxxQBi0UUUAFFFFABT4I2llRI1LMxwAOtMrsvhlpkt3rH2tCQsHHQYJI70AenaHazWunRRK7N8owZGyTVp0XH70rk8c+9Xc8/IvPr6UqruPK/QnmgCK1tba3UiJBn2/wAatYGOCABzkd6rFCrcHj0HNPUsPlwaALHmemcY5FMx8wBA4HFRkjcSpJIGM0q/OQScsKAOQ8YSvZ3HmRgMCOARxms/RNSNzEokVVc8MB6103iC3jmQhwrNjp6VydtZXkJaSGNmT+I+lAHZ2297RbqNvmU7WB6VuW8yzRqxbBxmuH0nU3gvPIl2+S/QnjmukjaPG9HyvXgUAaq9Sy7cL0oJOzIwCfWstNWt42KySr8oweelUdY8aaRpsbbrlHlCj5FOTn8qANq6YQQl5OMDkmvM/G/jJ4A9lZFSzKQx/u/WsHxR47vtXLxQL9nhPGVJyf8ACuNJJJJJJPc0AS3FxLcPumcs3vUVFFABRRQFLH5QTQAUUUUAFFFFAHZ/C8CTVrmJ87WiDfkf/r17G9uk9lJayjMbKUb6Yrx34UyEeIJoVTcZYeMdRhh/jXuUsOEO7I7HNAHkF9bR2OtG0IwmTA3urDGfyNedzxNDNJE4w6MVYehHBr134hWYjEV+hJYsA/sR/wDqrzTxQFOsSyp92YLL+JAJ/XNAHZWsJn/iO0nsOtaGm25ur+WOMhUQYP8AhUfh5AbNpGGAp+Unnk1u6DaeXJLIMAyHrnqKALDs3mRrGwESDkemOn8qn8LyPLfTFiSQvGfTikuEWMSBFUKOp4NJpTJDcF1OMnbn8KAOmaQZOATXpOh+Ijofwxl8p/8ASWuWjTHO0HHP868u8wAENnaKUzObZog5KA5wScUAF1I0rmSVtxck5xknPNVHzwEOAP0qc/KFBwSccgdDSgHJJ6k8ZFAEYk2feyT27isPxxpMur6LNbWip55GVz3wQcVvkvg/3s8VGTIXA7evSgD5xvLWeyuHguomilQ4ZWHSoQCxAAJPoK9f+JPhxdQsPt9og+1QAs+Orp/UivIOh4P5UAFFFFABXZ/DG+Ntqs0TShEkTO0nG4iuMoBxyDQB9JxMWQPu96lDjPDE+vtXiWmeOtUsbTyG2T44Dv1A9PerU3xCv2jxHBErdySTQB7A8gL4DD15qP7RGuCzgHoRmvBLzxDql3K0j3cilhjCEgVTS8uAVP2qUNnuScUAfRAuI85Z1xj8hXL+L/GdrpdtJHZSiW7dcLt5C15PPq940RhF3Iy55bpms0kk5JoA63wvreo3/iq0W+vp5Y5pMOjOdp4OBj64r3K00uOezmEcf7teCR2zXzVpMrw6pZyx8OkyMPqGFfTOm608VtJFC48uQenT3oA43UdFQS7oiwC9OvWljS5WMKWGwdSDjiti/v4DI0TbhkZyBxXF+L/EdrbaTeWti7NcuBGGHRM9T+WaAOf8ZPcWU0rQX4Ku3yqjc1xckjyuXldnY9SxyaQknqSaSgAooooAKKKKACgEgEAnB60UUAFFFFABRRRQB7N+ybo1trPxUaO9iEsMFhNMVPQncij/ANCr2bx9o/8AY3iG4tk4ikzIg7BSTgV5j+xX/wAlT1T/ALA0v/o+CvcvjZDnW7CUAY+z4Pr94/40AeF+OrYDwsJWdC8s0/loAS37ry9x9Mfvk7+vpXkHiOLNpp1xgZdGQkH0bj9DXt/iy3W60KJI5UU2zXzSBgeRKtrtxgf9MHz+H4eKasC/hu0c8FLhk49xn+lAHpOlWgTTre3ycL8z/Wt60QIADhQ3c96oWiEIWA257H0rTtsvbgL1A6en50AVJ1wrDqDnP/1ql0dRJPNwcAdh2xSTJ13DqMinaZIEuUjROWHzH1oAuXY8tEkbODzWhodrLq0ggtULznkKvWql7Cz2zYwR1A9DXSfBNh/wnNpHLgq6ydR/snigDC1Czms7iWK5RkkQ4IPBzUakgDpgda9W+NmgrFLaatbRKiv+6m2jHzdQx/DivKTknB/MjpQAhcFdu7A68VESrfdx9amZFznA9KgZcZJPfgUAMXYylGbcDwQK8K8bacul+Jby3jGIiwkT6MM17sEHUAZ9OhryX4tQMviCGYKdjW6qWx1YM39MUAcPRRRQAUUUoUkE9hQAlPhTzJo4y6pvYLuY4C5PU+1bXhS1sJrwTahdRRpG3+qkXO+ofErWlxrNw2lp+4B42rgH3FAGdewrbXcsKypMqMVEiHKt7ioaKKACigAkEgHA6mpbW3e6nWKIZZvXtQBd0CzuLrUomtYJJjCwkYIucY5Gfyr0O2urybVrSxZ3hGA8qbccD+HmoPh/HFYO9qVzPKR84HX2rtZdHVryO72KZEyNy8ZFACXbmUfISMAAAfzriPGmlifTbidF2tEu/gfeA9a7mWB4zscEkDkisHxRPbw6HfozfO8DhR6HBoA8ZooooAKKKKACiiigAIA6HNOijeVwkalnPQCm06N2jcMjFWHcUANooooAKKe6BYo3Dgls5X0plAHvf7F8yx/Fa/VjzLpEyL9fNhP8ga94+Mzl9bs4lI+W33H6lj/hXyP8INYutD8Qz3mnSPFdCHasidQCwyPxr6D8TeIJtcvZ72QncY9iAkfLjp/OgDh9eJj0nU5ScggqoPTpivH9TQr4SQ9jdr/6A1ep+NpfsWhfZnfMjnk+vrXmXiM+V4X06Pj97O7nA9Bj+poA9Os5FlsY5Y5BIjoGVgCMjqP85rQtB5kCb2IbAJ2965jwZeLd+GLL590iKYio5I2nGPywfxrprZlXGflI454oAkm3hcEDjrnnNVYtqTCTBypBX2q7cMqp8x+boBng1S67XI2qe1AHQ4DYHByMgjoak8J3f9ieJbK+Vflim3H0x0P6E1U01/NgKHBK8DPUVHqReBfMGCR1BPSgD6L+I/k33gG8kVsoyJKhHf5gf5V8+SIQ5zye3tXVSeMhqPga10+CZvtFsdjLtwGjxx+WK5dZDIg2ZHv6UARSHLBicn1AzioW25wRwecZ71M2DgDlj19KhdOMjPBoAY659cfXmuF+KAEehjfyryqBjqOp/pXazybCOT8x4rifixIf+EfgBK5edeO/AagDyU4yccCiiigAq5Y3FvFa3kdxGztIgEWOitnqfwzVOigArT0DWZtFuZJoER96FCr9MVmUUABOSSe9aukaLc6kEa2UOC5UgnGOOprKr1T4fRG50tJI4lRUyOD1oAtaB4LitI3MhQtNH5bAHPXr1p+n+Cd2t2mkaREzSXPVzya6+JjGNrDAAySK7b4Irb6h4580pl4ImbJ69DigDq/CngLwt4Lgga5tPt+sYVpPNwyq+OgB4/nXXf8ACQW93G1tJbW7Qt8rIUyuPSsbUFjuJ2lbJcOwmPbk8YqezsBJGzNCDnO3GM0Ach8RvhraXmjXGpeEmmiuowCbMNkMo6le+e+PavlrxhptxYJIZCSkiMevQ8ZzX2po1z9m1a3APGQGA5yCa+U/jxYmx8ZeILe3ytukruEzwuWBwPzoA8eopBS0AFdDpk+kJ4ZvYrlFOoOSY2ZckHjG09vesJ4wkSP5iMXz8oPK/Wo6ACiitHUrm0lt7eO0to4mCDzSAc7vYknigDOooooAKKKKACiinRo0jqiDLMQAPegDufh/bpbWk17csEjlcRqSewyTXqem6rBexNLbMDBF95z06V5jfabcW1vYaLCAJ0QM4/2jyea6nW3h0XS4dKt2KlkzMV54xjrQBj+LtRGpXylXPlg7h9B0/OuS8aSbJLCzww8mDcwPq53fyxW3psP9oaiqOMQgGR+21FHP6Vx2uag2qarc3j5/eN8oPZRwo/ICgDsfhffEi7sSxyMSoO3o39K9BUgfOrA+gJrwvR72XT9QhuIWwynB+nevZNH1KHUbMPGyo4+8vcUAb0MiTBTgbug+tRzxfMXVsEjOMVnLctCN0IJYc+2R2NX4LpZkUOqrLx8u/wDOolNRaT6mtOjKpGUo7RV396X6j7W5MMgfjsNvrWkskd/AcEgtxtPY1kSr8p2FSfSo45pba43qwKfxLxVmQtuTYXskZXCFjwe3uK1Yn2yMQTsI3ZNUdUjNxH50WSduSPUVa8P3sUlwYHUN5yGNFwD8xU4/XFTOXLFvsaUYKpUjB9WkXF2MA6kkEZUnpVaRgT8xHFdl8TfCcnhS8S4tEY6JKVUOOsTnPyn8s59640orD5AGGPXrRG9lzbiqcnO+Ta+l97EVyUSCSY4VUBY+uAMmvBPFGtSa5q0t0wZIvuxx7shQP85r3PWLeWfT57eL5WnRoyc9iMV5lc/DXUEhLW91DLKP4CNv61RBwVFOljaKV45AVdCVYHsRTaACiiigAooooAK9t+HUSrocbCMBCBg4xk+teUeG9Hm1jUooI0byyfmYDge1fQukaWlppscEYG1FA4oAgnUuh/hHXFdh8BopYvFWotAu4/Zjjtzisrw9oV14g1QWVojALhppSPlROhJr2nwF4Q03QL2S50+SWUTRAiRiMHkjtQBYtLN4Lkm5gMQJZmk25JznFTRGMShBw23gHrxWl4l1vTtDs2m1O5EaMMCIYLP9BXmC/E3QVvzt0W7KK2DN52Tj1x0oA6u+0+eDUo51WTywQQ6qRjmvmT9pWxl/4WHfYBEc6Ahj0J2ivsXQtXsPEGmpeafIJoCxHIwVYdiOxrjPF/w30TxZq93Nq4mwAqp5bAYZup/PFAH56EYPTFFd38Y/A114E8X3NhMrG2c74JdpCup7iuEoAKKKKACiiigAooooAKKKKACvbf2YPhqPGXih9X1OJho2lFX5X5Zpv4Uz6D7x/D1rynwn4fv/ABR4gsdH0mIy3d1Isa/KSqAnBZsZwozkmvvvTtK034W/CyPT7V1xa2+zeFCtcXDDlsepbnvgD2oA+f8AxhFZ2njrxDq6Igto5zbwKOhxhTj8jXk+sXjy3DliXZ2LvznHov4V1Xi/WTnyo13xo3JHO5z1rl9LhiIn1C+JFnZjzHBHMrdkHuaAIdbn/sjw4sIci+1Hl1Bw0cIPQ/738q4mr2talLq2pzXk4CtIeFHRQOAB9BiqNABXY6FfzRpHeWwHmgbJcHGcd8Vx1aWgtI16sMThXlO1cnGW7D8aAPWLK+jvI90RLO3BBqbULOWSZHtnMN1EgTJOQR1x+ZrjrIzS6hBG5aGTzFVgoI4zyfyzW6viErqFxFLGBsdlD5zkA4zWbd6iXl/X6nRGNqEpd2l+Dv8Aobmlagt1E0cmEukOHGP1BqzdRsyM4O09eBWJeRJdRrdW0qrOBxjofxp2na+GAg1JBBIpxvJOD+daHOXItfigHlTHDKcdM1HYXsL6jJJbMVZAJEf+62eKh8TaImoRJPbSDftyAvIeuatvOtbG4DxFXaRIcnjOMsce/C/nWdVXjbudGFlyVVPtd/NJtfifbXhm9sviD4HA1SFZUmzDcR4xh1IOR/46a8U8X+FL3wnqLQTSLJauzNbuO6A8ZHYgEVh/CHxu/h/VYJJVMkbAxypvI3KccgevSvpLxTpdt4v8LZtmSQuomt5FwecdM+/Q1oc581MSWDHnjP4VXknOMRnBrS1C0aC6lgmBWRCQQeMGqEkYDcDP1oA8U8a6HcadqM1w7K8U8jOCOoyc8/nXNV7rrtmLnS7iCTPzqw3MM4yK8Nnj8qeSPOdrFc+uKAGUUV3fg3wqk8f2rUonyDlY2wARjqQaAOEwfQ1s+HfD8+tzhYXjRQRncTnrXrV/4d0/UrURzwKAowGQAMPocVo+HdCstKh2WYYqMD58Zx9aAF8L+HYdCtAkSLuPU5zzXqHgbwfd6/Ms5Ij01W2ySbuTx0UetM8BeCpvENwtxOGh05Sd0gH3j6Ln+de8wJDboltboiKgACKMBRQBiHTdG8K6BdtGEsbURnzZuWYjHUnqT1qp4Iv49Sto30qKWPRolZIzMRvds5PHpzXi/wAYfiLLqHiaPT9Ot47jT9OnIbDbhM4PJOOMDBA+pr2HwJ400zxlpwFur2N2hO60Z8OMdxjqKAPKPjjf3T+N5baZSIYbePys9MNnn881w8FwiwYJAI6ivoj4s+H7DVvDzz3A8u9gGIJgBnn+E+or5mtLG5m1n+z3inSYNh/3ZwFz96gD2z4BvfZ1N+BpQUsQTz5vGP8Ax3Nel6i0tlI93HbSXlm+JnEbgPGyjgqDjI9s1zvgm88N6Lpn9iWUrlIEaeV7gDL88k469vyrm/EHxSvhcz2+g2dqkMbEefPnLD1A4oA2PFnh/wAN/GPwlcxrn7RGHhhnZCsltLwcEdxkDjmviX4leA9X+H/iB9M1mMENloLhPuTp/eHp7g8ivpay8Uappvi2111pG8mU/wCl28ZKpMvIye2RkkZr2u8tNE8ceG41vLS21GwuUDbJFVzGSOoznDCgD80aK+gvip+zdq3h9Be+DpZ9asicNbMn+kx+/HDj6AH2rwCaKSCV4pkaORDtZWGCp9CKAGUUUUAFFFOjRpHCoCWPQCgBtABJAFaz+HNVDxrHZTTb/umJSwJ9K+pv2ePgUdHmtPFPi1GGox5e2sGUFY8rwz5/i5OB260Abn7Lvwrn8H6VJ4i1oJ/amqQJ5UOObeI/Ngn+83yk+mMVlftDeN1nuf7IsHJW1LbzjjdjBP4dB+Ndt8aPiVa+HNLn07TpEm1CUNHJtfBhGPX15r5B1O/udX1ArGHkllfoCTn/AOtQBGizanfrb2Qyz8pk8j1JNZni3U7d0h0zTS/2a3z5zNx5svQn6en41b1zUI9ItZNOs5N9/Jjz7iNseWM52KRzngZ/KuQoAKKKKAChSVYMpwQcg0UUAdZ4e8RXMmoq9/FHd+TG83mMuHAVC2Mj1IAyc9aQXMd9bSS6assbR8yW5O7av94HuKz9CjCaNrt0TykCQgf77jn/AMdrJtbia0uEmt5GjlQ5DCs4u85P0X6/qdFRONKCfW7/ABt/7adJpmpXVpgRyZXP3T0roo9QsNYtmhnHlTkYGeK5KPVrO5iIvYGiuM586DofqvH6VNLZSx2kd1GRPbP0ljJIBz0Poa0Oc6ewv77Q7hYrzfNZ5yuOcCuluLW11uyje3baXzIoPXd6/wAvyrzy01S4iBTdvhwAVY8/StE332qSF7KYW88KhVRuOBk8H8TUTi5NPt/kbUqihGae7Vl96f5Kx0CWk9nOkkoAmQ4LdiK9l+FHjufQJhaX7tNpUrDI6mIk/eH9RXjWneJnDfZ9ajZiOC4Ga6vTTHIqy2rB4jyB3qzE+hvHnhG08R6d/a2jiNrlk8zdGcidf8a8PvLOS2donRlZTggjBFdB4P8AH974ZuFiYmawLAyQHqB0JX0P869HudP0D4i2D6ho8wiv8hW8zhhj+8uffrQB4XLAsgKleDxzXM3vgLSLyZpGieFmJJMbEZP0r0zxF4evNBvDHqMYQHO1x0YDuDWDLIrSARkEdhmgDlbLwPomnyrIkRllHQyMWx+HStMweSP3Xy/StWQktyM+tRSJ82Tj8DQBTjEgQgyY9q674d+HpvEGrrbkZhTDylem3cM1z0EBkbIC+gr0zwH4v0TwpYTwTRyS6g4GREuRxngnt1FAHtMENrptkscQjgtol+iqK8H+K3xW2yXOieGkdVmyJrzPzSdj5ft2z+VZHxA8d6lrVnItxKYbE4It0AwTnjPrXFppUEmye7XfKRx7f5zQA23ktraGPFu4eQH747/5NXdO1O5sLtLizldZI8kMp2uv0qO3gmjvFkgQCNV2lTzn35q/NbhADhfw70Ael+FPFdn47totD1y7MGsRnNtOB/rPUEdN2B+NdvafD7TkiJuJppJyMeYvy4HpXzyukxSsZYHaC7Q71ljcqykcg/ga9v8ACXjhr3wJqN5qTD+2NLgKz5AAkfB2OB0wxH55oA434o6j4e8Kak2ladFO2rzRqZZPM3bUJztx6nAPTpXm8WoPdq9wYyyqeI88E+9XbixSa/mu76RrjUZzumuJTlmP+QKlhghMQVHRWHRCMfnQBY1XxBK+gpbQWRSV4ypVecH19fpXI+HZ/GWj3s13peoXNgp5Khhh+RwVIrpWjjD5IBOPwpyXabvKVlBX3oA9D8IfGS5mtFj1vTzJcJ990Hlk/hjH5V5b8bNE8N+MNWXVtHgfTr10ImG3iVs8MQO+OM1ce5AUjjjg4qnExmDsxZEzjb7etAHi2peDb22bEJ838OPzrPTw5qZmWMwbQTyxIwK91msFkYvFLjjocECqkuiR3KASbGkP8S5X+VAHmVt4GJmBur6NYfUDn9a6Dw/4FtU1GMWxn1CcnEaKmOf616H4Z+Hljqd2janrUGn2SHMihi0jj0BPSvRR408B/DOweDw/BJd3uPLaUtkt9XJ6Z7CgDe+Hfw6tfD0C6r4jMP2lAGWN2ASAerHoT+lc58U/jhbaeJ9P8NvulHDXQxxz/CP614v4/wDi1rXijdHcXPlwA/JDGMIP8a4r7NPJYveahMtrZ5+Zn+8/+6O9ACanqd94i1WQqZZJpmLNv757mqmp6rBosD2ekuJL5hsnuwchR3VP6t+VUdV19BFLaaLGba0cbHkP+smH+0e3fgVz1AAcnknJooooAKKKKACiiigAooooAKsWd5cWUoktpXjIPIB4P1Heq9FAHQwazaXspGq2ojZuPOtRtIPqV6H8MVdi077TG0mkXEd6qjLKDtkA/wB08/lXI0qO0bq6MVZTkEHBBoA6dL+4t5TG4DJj7kgyK1tK1hbWQNBM0MhPKHOz/wCtWBbeJZmj8rVII7+P+/Idso+j/wCINXI4dMvY92n6gY5iP+Pe7G059m+6f0oA7+28QxsgN9CP99PmArT0vV2inFzo18Yp1HGxyje/pXlk1pf6Y4MqTRE45XlD+XFS22pyPIA0anqd8Z2tQB9P6R8WftFp9g8XadHfWzKIy4T58YwTz1P5fWoprHwJfxM2i6tdWV1nIhuUJX6A4/qa8F0/xA6skZkEi+j9R+NdHb6xZysGLCNiO3SgDttR0xrRv9fE6/3kbNZ5QgcEAep5rLtL1CwHmgx49cir0VykrcSMO33aAJ5GEaE5x684qmmxWMqDLMfSpi8BVVcF8HOW7Vn3uoWFuxBvEiIySMZ/lQBpeWtxGq3AJU8+vNTxxqqbfu+2M/lXLw+K9MgjEf24ysP7sZJxXR6deNcQrJHEVHq/BOaAL8ETBTt4PU571HeXKWluJZCq/MBufp1pHu0jb55UBHX5ulUbzVtLBH2iZH28jIyKANQnP7wsfmOc561h3WrWEEtzDPgSOBsbHOQarXnifzlMelQvOfVFP/6q5C+1aJLhjf3VnbyZyyli56+i5oA7iy1iNpVR92APvmrrXdmRzKgx7815PceItNiL7NQnk9oLfGfxY5rOk8S6fknytSmOf4p1T+QNAHq17q1hYI+w72Az14/WuP1vxVLcoyRC1hXONxPzfpXHyeINOZif7HZjn/lrds38lFA8TwKNo0OwKj+8XJ/nQA6R2Mm77Yp7bgzYpyT+SRnUHHsisT+dQ/8ACTxhSE0XTBn1Vz/7NQPFcirhNK0oe/kEn9WoA0Y9TCfLFc3sh7DeRSxajqMjH7PDdSN/tMzf4Vlt4v1IZ8hbO3JGMxWyf1BqnL4j1iUktqNyueyPsH5DFAHWQ2uuyxmSVVt4h1eVwgx+JqncvpUTv/amqvO6/wDLK0BPPpu6Vx0881w+6eWSVvV2LH9ajoA6JvExtdyaTZwW6dpJVEkv13Hp+VYd1dXF3L5l1NJM/q7Fj+tQ0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBoWOtajYxeTb3cogznymO5P++TxWrH4isp1xqGkxeZjBltW8s/lyK5qigDprf8Asm8O2LUJ7M9vtMYKn/gSn+laCaNdof8AQ9R0+5U9PJnB/SuJooA7hf7Ztxt+xSkL0Man+lJJq2px8C31BCR2LD+lcUkjx/6t2X6HFXrTWtRtBi3vJkHXrn+dAHQvqt3KNsgvjzyCzc/pUGZHbctpdOTyeCfz4qiPFmuAYGoSY/3V/wAKil8S6xKCHvpCCNpwAOPwFAG7DDertaHTZkPqVI5ragl1JoT9r1W0tFByRcXOD9MZrzWSaWX/AFsrv/vMTUdAHbXut2cUmG1C6uG7/Z4gqn/gROf0qlceKolhMdnpyFsf626cysPoOAK5aigDRvNc1O7iMU99OYSMeUH2pj/dHFZ1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT image shows extensive pleural metastases from melanoma with an associated soft tissue mass involving the right chest wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Donohoe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_24_12687=[""].join("\n");
var outline_f12_24_12687=null;
